CA2921864A1 - Rna viruses expressing il-12 for immunovirotherapy - Google Patents
Rna viruses expressing il-12 for immunovirotherapy Download PDFInfo
- Publication number
- CA2921864A1 CA2921864A1 CA2921864A CA2921864A CA2921864A1 CA 2921864 A1 CA2921864 A1 CA 2921864A1 CA 2921864 A CA2921864 A CA 2921864A CA 2921864 A CA2921864 A CA 2921864A CA 2921864 A1 CA2921864 A1 CA 2921864A1
- Authority
- CA
- Canada
- Prior art keywords
- recombinant virus
- family paramyxoviridae
- polynucleotide encoding
- cancer
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 187
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 149
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 149
- 239000002157 polynucleotide Substances 0.000 claims abstract description 149
- 241000711504 Paramyxoviridae Species 0.000 claims abstract description 144
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 123
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 123
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 98
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 96
- 229920001184 polypeptide Polymers 0.000 claims abstract description 95
- 201000011510 cancer Diseases 0.000 claims abstract description 62
- 230000004927 fusion Effects 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000028993 immune response Effects 0.000 claims description 42
- 241000712079 Measles morbillivirus Species 0.000 claims description 36
- 150000007523 nucleic acids Chemical group 0.000 claims description 33
- 239000012190 activator Substances 0.000 claims description 31
- 108090000663 Annexin A1 Proteins 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 16
- 102000018358 immunoglobulin Human genes 0.000 claims description 16
- 229940121764 CD86 antagonist Drugs 0.000 claims description 14
- 229940123828 CD80 antagonist Drugs 0.000 claims description 13
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 101000959737 Mus musculus Annexin A1 Proteins 0.000 claims description 8
- 101000583937 Mus musculus CDK-activating kinase assembly factor MAT1 Proteins 0.000 claims description 8
- 101001038345 Mus musculus GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 claims description 8
- 101001090482 Mus musculus Glutathione S-transferase LANCL1 Proteins 0.000 claims description 8
- 101000808124 Mus musculus Uroplakin-3b Proteins 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims description 6
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 claims description 6
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 claims description 6
- 101000912009 Homo sapiens Cyclin-dependent kinase 5 activator 1 Proteins 0.000 claims description 6
- 101001038346 Homo sapiens GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 claims description 6
- 101001090483 Homo sapiens Glutathione S-transferase LANCL1 Proteins 0.000 claims description 6
- 101000980900 Homo sapiens Sororin Proteins 0.000 claims description 6
- 101000808126 Homo sapiens Uroplakin-3b Proteins 0.000 claims description 6
- 102000048091 human CDCA5 Human genes 0.000 claims description 6
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 241000712045 Morbillivirus Species 0.000 claims description 4
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 208000022136 colorectal lymphoma Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 208000010749 gastric carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 141
- 229940117681 interleukin-12 Drugs 0.000 description 94
- 241001529936 Murinae Species 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 35
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 239000012634 fragment Substances 0.000 description 30
- 230000027455 binding Effects 0.000 description 26
- 239000000427 antigen Substances 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 210000002865 immune cell Anatomy 0.000 description 23
- 210000004988 splenocyte Anatomy 0.000 description 22
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 20
- 239000005557 antagonist Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 108700019146 Transgenes Proteins 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 239000002955 immunomodulating agent Substances 0.000 description 10
- 229940121354 immunomodulator Drugs 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108010079855 Peptide Aptamers Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 206010039509 Scab Diseases 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000002601 intratumoral effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 241001493065 dsRNA viruses Species 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000036269 ulceration Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 239000012124 Opti-MEM Substances 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 101150118163 h gene Proteins 0.000 description 5
- 230000007595 memory recall Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 4
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229940124862 Measles virus vaccine Drugs 0.000 description 3
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 244000309459 oncolytic virus Species 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 101710169105 Minor spike protein Proteins 0.000 description 2
- 101710081079 Minor spike protein H Proteins 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 102220080600 rs797046116 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 230000004222 uncontrolled growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100072394 Homo sapiens IL12A gene Proteins 0.000 description 1
- 101100018679 Homo sapiens IL12B gene Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 1
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100072398 Mus musculus Il12a gene Proteins 0.000 description 1
- 101001076432 Mus musculus Interleukin-12 subunit beta Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 101000959729 Rattus norvegicus Annexin A1 Proteins 0.000 description 1
- 101001038344 Rattus norvegicus GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 1
- 101001090485 Rattus norvegicus Glutathione S-transferase LANCL1 Proteins 0.000 description 1
- 101100018666 Rattus norvegicus Il12a gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710180188 T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- -1 cytokines Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 208000022982 optic pathway glioma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.
Description
RNA viruses expressing IL-12 for immunovirotherapy The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and, thereby, treating cancer in a subject afflicted with cancer.
Interleukin 12 (IL-12) is a heterodimeric polypeptide interleukin consisting of two subunits, p35 and p40, encoded by two separate genes, IL-12A and IL-12B, respectively.
IL-12 is produced in response to immune stimuli by dendritic cells, macrophages, neutrophils, and by human B-lymphoblastoid cells, and has been known as an important stimulator of immune cell activity, in particular of T cells and natural killer cells, which are, among other effects, stimulated to secrete IFN-7 by IL-12. IFN- y, in turn, is known to stimulate expression of immune checkpoint blockade proteins on non-immune cells, e.g. of PD-L1, a mechanism used by cancer cells to evade the immune system (Abiko et al. (2015), British journal of cancer 112(9): 1501; Quetglas et al. (2015) Cancer Research 75(15 Supplement): 281).
Due to the known immunostimulatory effects of IL-12, it was attempted to use a recombinant measles virus expressing both subunits of IL-12 as a vaccine to improve immune response against measles virus. However, it was found that the transgene had a detrimental effect on the neutralizing antibody response and that lymphoproliferative responses were not improved (Hoffman et al. (2003), J Infect Dis 188:1553).
Interleukin 12 (IL-12) is a heterodimeric polypeptide interleukin consisting of two subunits, p35 and p40, encoded by two separate genes, IL-12A and IL-12B, respectively.
IL-12 is produced in response to immune stimuli by dendritic cells, macrophages, neutrophils, and by human B-lymphoblastoid cells, and has been known as an important stimulator of immune cell activity, in particular of T cells and natural killer cells, which are, among other effects, stimulated to secrete IFN-7 by IL-12. IFN- y, in turn, is known to stimulate expression of immune checkpoint blockade proteins on non-immune cells, e.g. of PD-L1, a mechanism used by cancer cells to evade the immune system (Abiko et al. (2015), British journal of cancer 112(9): 1501; Quetglas et al. (2015) Cancer Research 75(15 Supplement): 281).
Due to the known immunostimulatory effects of IL-12, it was attempted to use a recombinant measles virus expressing both subunits of IL-12 as a vaccine to improve immune response against measles virus. However, it was found that the transgene had a detrimental effect on the neutralizing antibody response and that lymphoproliferative responses were not improved (Hoffman et al. (2003), J Infect Dis 188:1553).
- 2 -Oncolytic viruses (OV) which replicate selectively in tumor cells are an emerging modality of cancer treatment. Aside from direct cytopathic effects and lysis of tumor cells, interactions of OV with the immune system can trigger systemic anti-tumor immunity. OV have been modified to express immunomodulatory transgenes to further enhance these effects (Melcher et at., Mol Ther. 2011, 19: 1008-1016). The vaccinia virus JX-594 and herpesvirus talimogene laherpavec (TVEC), both harboring GM-CSF, have shown promising results in clinical phase II and III trials (Heo et at., Nat Med. 2013,19: 329-336 and Andtbacka et at. J
Clin Oncol. 2013, 31, suppl; abstr LBA9008).
RNA viruses, in particular members of the family Paramyxoviridae like, e.g.
measles virus (MV), have also shown potential use in oncolysis. Viruses of the family Paramyxoviridae are negative-sense single-stranded RNA viruses and include human pathogens like, e.g. human parainfluenza viruses, mumps virus, human respiratory syncytial virus, and measles virus.
From wild type measles virus, several non-pathogenic strains, including a vaccine strain, have been derived, which have been shown to remain oncolytic. The measles virus vaccine strain has been developed as a vector platform to target multiple tumor entities and several clinical trials are ongoing (Russell et at., Nat Biotechnol. 2012, 30: 658-670).
Recently, the capacity of oncolytic MV encoding GM-CSF to support the induction of a specific anti-tumor immune response in terms of a tumor vaccination effect was demonstrated (Grossardt et al. Hum Gene Ther. 2013, 24: 644-654.).
There is, however, still a need in the art for improved cancer therapies, in particular for improved oncolytic virus therapies. It is therefore an objective of the present invention to provide an improved oncolytic virus, which fully or partially avoids the short-comings of known oncolytic viruses.
Accordingly, the present invention relates to a recombinant virus of the family Paramyxoviridae, comprising an expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12.
Clin Oncol. 2013, 31, suppl; abstr LBA9008).
RNA viruses, in particular members of the family Paramyxoviridae like, e.g.
measles virus (MV), have also shown potential use in oncolysis. Viruses of the family Paramyxoviridae are negative-sense single-stranded RNA viruses and include human pathogens like, e.g. human parainfluenza viruses, mumps virus, human respiratory syncytial virus, and measles virus.
From wild type measles virus, several non-pathogenic strains, including a vaccine strain, have been derived, which have been shown to remain oncolytic. The measles virus vaccine strain has been developed as a vector platform to target multiple tumor entities and several clinical trials are ongoing (Russell et at., Nat Biotechnol. 2012, 30: 658-670).
Recently, the capacity of oncolytic MV encoding GM-CSF to support the induction of a specific anti-tumor immune response in terms of a tumor vaccination effect was demonstrated (Grossardt et al. Hum Gene Ther. 2013, 24: 644-654.).
There is, however, still a need in the art for improved cancer therapies, in particular for improved oncolytic virus therapies. It is therefore an objective of the present invention to provide an improved oncolytic virus, which fully or partially avoids the short-comings of known oncolytic viruses.
Accordingly, the present invention relates to a recombinant virus of the family Paramyxoviridae, comprising an expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12.
- 3 -As used in the following, the terms "have", "comprise" or "include" or any arbitrary grammatical variations thereof are used in a non-exclusive way. Thus, these terms may both refer to a situation in which, besides the feature introduced by these terms, no further features are present in the entity described in this context and to a situation in which one or more further features are present. As an example, the expressions "A has B", "A
comprises B" and "A includes B" may both refer to a situation in which, besides B, no other element is present in A (i.e. a situation in which a solely and exclusively consists of B) and to a situation in which, besides B, one or more further elements are present in entity A, such as element C, elements C and D or even further elements.
Further, as used in the following, the terms "preferably", "more preferably", "most preferably", "particularly", "more particularly", "specifically", "more specifically" or similar terms are used in conjunction with optional features, without restricting alternative possibilities. Thus, features introduced by these terms are optional features and are not intended to restrict the scope of the claims in any way. The invention may, as the skilled person will recognize, be performed by using alternative features. Similarly, features introduced by "in an embodiment of the invention" or similar expressions are intended to be optional features, without any restriction regarding alternative embodiments of the invention, without any restrictions regarding the scope of the invention and without any restriction regarding the possibility of combining the features introduced in such way with other optional or non-optional features of the invention. Moreover, if not otherwise indicated, the term "about" relates to the indicated value with the commonly accepted technical precision in the relevant field, preferably relates to the indicated value 20%.
The terms "virus" and "virus of the family Paramyxoviridae" are known to the skilled person.
Preferably, the virus of the family Paramyxoviridae is a member of the genus Morbillivirus.
More preferably, the virus of the family Paramyxoviridae is a measles virus (MV), still more preferably an MV of strain Edmonston A or B, preferably B. Most preferably, the virus of the family Paramyxoviridae is an MV of vaccine strain Schwarz/Moraten.
comprises B" and "A includes B" may both refer to a situation in which, besides B, no other element is present in A (i.e. a situation in which a solely and exclusively consists of B) and to a situation in which, besides B, one or more further elements are present in entity A, such as element C, elements C and D or even further elements.
Further, as used in the following, the terms "preferably", "more preferably", "most preferably", "particularly", "more particularly", "specifically", "more specifically" or similar terms are used in conjunction with optional features, without restricting alternative possibilities. Thus, features introduced by these terms are optional features and are not intended to restrict the scope of the claims in any way. The invention may, as the skilled person will recognize, be performed by using alternative features. Similarly, features introduced by "in an embodiment of the invention" or similar expressions are intended to be optional features, without any restriction regarding alternative embodiments of the invention, without any restrictions regarding the scope of the invention and without any restriction regarding the possibility of combining the features introduced in such way with other optional or non-optional features of the invention. Moreover, if not otherwise indicated, the term "about" relates to the indicated value with the commonly accepted technical precision in the relevant field, preferably relates to the indicated value 20%.
The terms "virus" and "virus of the family Paramyxoviridae" are known to the skilled person.
Preferably, the virus of the family Paramyxoviridae is a member of the genus Morbillivirus.
More preferably, the virus of the family Paramyxoviridae is a measles virus (MV), still more preferably an MV of strain Edmonston A or B, preferably B. Most preferably, the virus of the family Paramyxoviridae is an MV of vaccine strain Schwarz/Moraten.
- 4 -The term "recombinant virus", as used herein, relates to a virus comprising a genome modified by biotechnological means as compared to known, naturally occurring, virus genomes. Preferably, the recombinant virus is a virus comprising a genome modified as compared to naturally occurring virus genomes. Preferred biotechnological means for modifying a viral genome are known to the skilled person and include any of the methods of molecular cloning, in particular recombinant DNA techniques including, without limitation, cleavage of DNA by restriction enzymes, ligation of DNA, polymerase chain reaction (PCR), cloning of viral genomes, and the like. It is understood by the skilled person that viruses of the family Paramyxoviridae have a single-stranded (-)-RNA as a genome.
Accordingly, the genome of the recombinant virus of the present invention, preferably, is obtained by cloning an expression vector as described herein below comprising an expressible nucleotide sequence encoding said recombinant virus genome, followed by expressing said expressible nucleotide sequence encoding said recombinant virus in a permissive host cell.
Alternatively, the recombinant virus genome may also be expressed in non-permissive host cells, e.g., preferably, from rodents or other higher eukaryotes. Preferably, the recombinant virus of the present invention is a recombinant virus of the family Paramyxoviridae, more preferably a recombinant Morbillivirus, most preferably, a recombinant measles virus (MV).
As will be understood by the skilled person, the recombinant virus of he present invention may comprises further modifications as compared to a naturally occurring virus.
Preferably, the recombinant virus comprises a polypeptide mediating a modified tropism and/or a polynucleotide encoding the same. More preferably, said polypeptide mediating a modified tropism is a fusion polypeptide of a viral membrane integral polypeptide or of a viral membrane associated polypeptide with a polypeptide mediating binding to a target, e.g. a cell, preferably a specific kind of cell, more preferably a cancer cell. Preferably, said fusion polypeptide comprises a viral hemagglutinin or a fragment thereof, preferably a membrane integral fragment thereof. Preferably, said fusion polypeptide comprises a single-chain antibody specifically binding to a target molecule, e.g. to Carcinoembryonic antigen (CEA) or CD20. Most preferably, said fusion polypeptide is a fusion polypeptide of a truncated viral hemagglutinin with an anti-CD20 single-chain antibody or with an anti-CEA
single-chain antibody. Preferably, the recombinant virus comprises a polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NOs: 4 to 7, 14, and 15. SEQ ID NO:
4 is an
Accordingly, the genome of the recombinant virus of the present invention, preferably, is obtained by cloning an expression vector as described herein below comprising an expressible nucleotide sequence encoding said recombinant virus genome, followed by expressing said expressible nucleotide sequence encoding said recombinant virus in a permissive host cell.
Alternatively, the recombinant virus genome may also be expressed in non-permissive host cells, e.g., preferably, from rodents or other higher eukaryotes. Preferably, the recombinant virus of the present invention is a recombinant virus of the family Paramyxoviridae, more preferably a recombinant Morbillivirus, most preferably, a recombinant measles virus (MV).
As will be understood by the skilled person, the recombinant virus of he present invention may comprises further modifications as compared to a naturally occurring virus.
Preferably, the recombinant virus comprises a polypeptide mediating a modified tropism and/or a polynucleotide encoding the same. More preferably, said polypeptide mediating a modified tropism is a fusion polypeptide of a viral membrane integral polypeptide or of a viral membrane associated polypeptide with a polypeptide mediating binding to a target, e.g. a cell, preferably a specific kind of cell, more preferably a cancer cell. Preferably, said fusion polypeptide comprises a viral hemagglutinin or a fragment thereof, preferably a membrane integral fragment thereof. Preferably, said fusion polypeptide comprises a single-chain antibody specifically binding to a target molecule, e.g. to Carcinoembryonic antigen (CEA) or CD20. Most preferably, said fusion polypeptide is a fusion polypeptide of a truncated viral hemagglutinin with an anti-CD20 single-chain antibody or with an anti-CEA
single-chain antibody. Preferably, the recombinant virus comprises a polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NOs: 4 to 7, 14, and 15. SEQ ID NO:
4 is an
- 5 -artificial MV genome encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein. SEQ ID
NO: 5 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the human p40 subunit of IL-12 and the human p35 subunit of IL-12 as specified elsewhere herein. SEQ ID NO: 6 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein, and a fusion polypeptide comprising a viral hemagglutinin and an anti-human-CEA single-chain antibody. SEQ ID NO: 7 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein, and a fusion polypeptide comprising a viral hemagglutinin and an anti-human-CD20 single-chain antibody. SEQ ID NO: 14 is an artificial MV genome derived from strain Edmonston B encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein. SEQ ID NO: 15 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the human p40 subunit of IL-12 and the human p35 subunit of IL-12 as specified elsewhere herein.
As used herein, the term "IL-12" relates to an interleukin 12 which is, in principle, known to the skilled person. Preferably, IL-12 is the heterodimeric IL-12 having the activity of stimulating the immune response of a subject. Preferably, the IL-12 is an IL-12 of a vertebrate species, more preferably of a mammal, even more preferably of a rat, a mouse, or a human, most preferably of a human. Preferably, the IL-12 has the subunits of rat IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc. No: NP_445842.1 GI:16758120, and p40 comprising the amino acid sequence of Genbank Acc. No: NP_072133.1 GI:12018288.
Preferably, the subunits of the rat IL-12 are encoded by a polynucleotide comprising the nucleic acid sequence of Genbank Acc. No: NM_053390.1 GI:16758119 (rat mRNA
expressed from the rat IL-12A gene) and/or of Genbank Acc. No: NM_022611.1 GI:12018287 (rat mRNA expressed from the rat IL-12B gene). More preferably, the IL-12 has the subunits of mouse IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc.
No: NP 001152896.1 GI:226874945, and p40 comprising the amino acid sequence of Genbank Acc. No: NP 001290173.1 GI:735997434. Preferably, the subunits of the mouse
NO: 5 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the human p40 subunit of IL-12 and the human p35 subunit of IL-12 as specified elsewhere herein. SEQ ID NO: 6 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein, and a fusion polypeptide comprising a viral hemagglutinin and an anti-human-CEA single-chain antibody. SEQ ID NO: 7 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein, and a fusion polypeptide comprising a viral hemagglutinin and an anti-human-CD20 single-chain antibody. SEQ ID NO: 14 is an artificial MV genome derived from strain Edmonston B encoding an IL-12 fusion polypeptide comprising the mouse p40 subunit of IL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein. SEQ ID NO: 15 is an artificial MV genome encoding an IL-12 fusion polypeptide comprising the human p40 subunit of IL-12 and the human p35 subunit of IL-12 as specified elsewhere herein.
As used herein, the term "IL-12" relates to an interleukin 12 which is, in principle, known to the skilled person. Preferably, IL-12 is the heterodimeric IL-12 having the activity of stimulating the immune response of a subject. Preferably, the IL-12 is an IL-12 of a vertebrate species, more preferably of a mammal, even more preferably of a rat, a mouse, or a human, most preferably of a human. Preferably, the IL-12 has the subunits of rat IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc. No: NP_445842.1 GI:16758120, and p40 comprising the amino acid sequence of Genbank Acc. No: NP_072133.1 GI:12018288.
Preferably, the subunits of the rat IL-12 are encoded by a polynucleotide comprising the nucleic acid sequence of Genbank Acc. No: NM_053390.1 GI:16758119 (rat mRNA
expressed from the rat IL-12A gene) and/or of Genbank Acc. No: NM_022611.1 GI:12018287 (rat mRNA expressed from the rat IL-12B gene). More preferably, the IL-12 has the subunits of mouse IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc.
No: NP 001152896.1 GI:226874945, and p40 comprising the amino acid sequence of Genbank Acc. No: NP 001290173.1 GI:735997434. Preferably, the subunits of the mouse
- 6 -IL-12 are encoded by a polynucleotide comprising the nucleic acid sequence of Genbank Acc.
No: NM 001159424.2 GI:746816821 (mouse mRNA expressed from the mouse IL-12A
gene) and/or of Genbank Acc. No: NM_001303244.1 GI:735997433 (mouse mRNA
expressed from the mouse IL-12B gene). Most preferably, the IL-12 has the subunits of human IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc. No:
NP 000873.2 GI:24430219, and p40 comprising the amino acid sequence of Genbank Acc.
No: NP 002178.2 GI:24497438. Preferably, the subunits of the human IL-12 are encoded by a polynucleotide comprising the nucleic acid sequence of Genbank Acc. No:
NM_000882.3 GI:325974478 (human mRNA expressed from the human IL-12A gene) and/or of Genbank Acc. No: NM 002187.2 GI:24497437 (human mRNA expressed from the human IL-12B
gene). In its natural form, IL-12 is a secreted interleukin, i.e. it is processed and transported from the interior of the producing cell to the exterior of the producing cell by said producing cell. Accordingly, IL-12 preferably is a secreted IL-12.
More preferably, the IL-12 according to the present invention is an IL-12 fusion polypeptide comprising a p40 subunit of an IL-12 and a p35 subunit of an IL-12, preferably comprising subunits as specified herein above. More preferably, the p40 subunit and the p35 subunit of said IL-12 fusion polypeptide are from the same species; i.e. preferably, the p40 subunit and the p35 subunit of said IL-12 fusion polypeptide are a rat p40 subunit and a rat p35 subunit, more preferably are a mouse p40 subunit and a mouse p35 subunit, most preferably are a human p40 subunit and a human p35 subunit. Preferably, said p40 subunit and said p35 subunit are comprised in the order N-terminus- p40 subunit- p35 subunit - C-terminus in said fusion polypeptide. Preferably, said p40 subunit and said p35 subunit are separated by a linker, i.e., the fusion polypeptide comprises the structure p40-linker-35.
The term "linker" is known to the skilled person and, preferably, relates to a short sequence of amino acids separating two domains of a polypeptide or two components of a fusion polypeptide. The skilled person knows how to select appropriate linker sequences in order to construct functional fusion polypeptides, e.g. from Xue et al. (2004), NAR 32 (Web server issue):W562. Preferably, said linker comprises of from 1 to 50, more preferably of from 2 to 25, most preferably of from 10 to 20 amino acids. Preferably, the amino acids of the linker are
No: NM 001159424.2 GI:746816821 (mouse mRNA expressed from the mouse IL-12A
gene) and/or of Genbank Acc. No: NM_001303244.1 GI:735997433 (mouse mRNA
expressed from the mouse IL-12B gene). Most preferably, the IL-12 has the subunits of human IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc. No:
NP 000873.2 GI:24430219, and p40 comprising the amino acid sequence of Genbank Acc.
No: NP 002178.2 GI:24497438. Preferably, the subunits of the human IL-12 are encoded by a polynucleotide comprising the nucleic acid sequence of Genbank Acc. No:
NM_000882.3 GI:325974478 (human mRNA expressed from the human IL-12A gene) and/or of Genbank Acc. No: NM 002187.2 GI:24497437 (human mRNA expressed from the human IL-12B
gene). In its natural form, IL-12 is a secreted interleukin, i.e. it is processed and transported from the interior of the producing cell to the exterior of the producing cell by said producing cell. Accordingly, IL-12 preferably is a secreted IL-12.
More preferably, the IL-12 according to the present invention is an IL-12 fusion polypeptide comprising a p40 subunit of an IL-12 and a p35 subunit of an IL-12, preferably comprising subunits as specified herein above. More preferably, the p40 subunit and the p35 subunit of said IL-12 fusion polypeptide are from the same species; i.e. preferably, the p40 subunit and the p35 subunit of said IL-12 fusion polypeptide are a rat p40 subunit and a rat p35 subunit, more preferably are a mouse p40 subunit and a mouse p35 subunit, most preferably are a human p40 subunit and a human p35 subunit. Preferably, said p40 subunit and said p35 subunit are comprised in the order N-terminus- p40 subunit- p35 subunit - C-terminus in said fusion polypeptide. Preferably, said p40 subunit and said p35 subunit are separated by a linker, i.e., the fusion polypeptide comprises the structure p40-linker-35.
The term "linker" is known to the skilled person and, preferably, relates to a short sequence of amino acids separating two domains of a polypeptide or two components of a fusion polypeptide. The skilled person knows how to select appropriate linker sequences in order to construct functional fusion polypeptides, e.g. from Xue et al. (2004), NAR 32 (Web server issue):W562. Preferably, said linker comprises of from 1 to 50, more preferably of from 2 to 25, most preferably of from 10 to 20 amino acids. Preferably, the amino acids of the linker are
- 7 -small amino acids and/or amino acids promoting turns in protein structure;
accordingly, the amino acids comprised in the linker, preferably, are glycine, alanine, serine, and/or proline.
Preferably, the linker has a repetitive structure; thus, preferably, the linker comprises of from 1 to 10, more preferably of from 2 to 5, most preferably 3 repetitions of an amino acid sequence comprising 3 or 4, preferably 5 amino acids. Preferably, the repetitive sequence of the linker comprises the sequence (glycinex-serine), with x= 3 to 6, preferably 4 to 6, more preferably 4 or 6. More preferably, the repetitive sequence of the linker comprises the sequence (glycine4-serine), i.e. gly-gly-gly-gly-ser (SEQ ID NO:1), preferably repeated as specified above. Thus, preferably the linker comprises or consists of the amino acid sequence -(glycine4-serine)n-, with n=1 to 10, preferably n=2 to 5, more preferably n=3. Most preferably, the linker has the amino acid sequence of SEQ ID NO: 8. Also more preferably, the repetitive sequence of the linker comprises the sequence (glycine6-serine), i.e. gly-gly-gly-gly-gly-gly-ser (SEQ ID NO 9).
As used herein, the term "fusion polypeptide" relates to a polypeptide wherein all components, e.g. p35 subunit, linker, and p40 subunit, are covalently linked and, preferably, are produced as a contiguous polypeptide chain. Thus, preferably, the fusion polypeptide of the present invention, preferably, is expressed from a single gene. Thus, the IL-12 of the present invention preferably is fused mouse IL-12 (FmIL-12), preferably comprising the amino acid sequence of SEQ ID NO:10, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:11. More preferably, the IL-12 of the present invention preferably is fused human IL-12 (FhIL-12), preferably comprising the amino acid sequence of SEQ ID NO:12, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:13. The terms "polypeptide" and "fusion polypeptide", as used herein, preferably encompass variants of said polypeptides and fusion polypeptides as specified elsewhere herein.
Preferably, the recombinant virus of the family Paramyxoviridae of the present invention further comprises at least one expressible polynucleotide encoding a further activator of the immune response, preferably an immunoglobulin or part thereof, preferably a secreted immunoglobulin.
accordingly, the amino acids comprised in the linker, preferably, are glycine, alanine, serine, and/or proline.
Preferably, the linker has a repetitive structure; thus, preferably, the linker comprises of from 1 to 10, more preferably of from 2 to 5, most preferably 3 repetitions of an amino acid sequence comprising 3 or 4, preferably 5 amino acids. Preferably, the repetitive sequence of the linker comprises the sequence (glycinex-serine), with x= 3 to 6, preferably 4 to 6, more preferably 4 or 6. More preferably, the repetitive sequence of the linker comprises the sequence (glycine4-serine), i.e. gly-gly-gly-gly-ser (SEQ ID NO:1), preferably repeated as specified above. Thus, preferably the linker comprises or consists of the amino acid sequence -(glycine4-serine)n-, with n=1 to 10, preferably n=2 to 5, more preferably n=3. Most preferably, the linker has the amino acid sequence of SEQ ID NO: 8. Also more preferably, the repetitive sequence of the linker comprises the sequence (glycine6-serine), i.e. gly-gly-gly-gly-gly-gly-ser (SEQ ID NO 9).
As used herein, the term "fusion polypeptide" relates to a polypeptide wherein all components, e.g. p35 subunit, linker, and p40 subunit, are covalently linked and, preferably, are produced as a contiguous polypeptide chain. Thus, preferably, the fusion polypeptide of the present invention, preferably, is expressed from a single gene. Thus, the IL-12 of the present invention preferably is fused mouse IL-12 (FmIL-12), preferably comprising the amino acid sequence of SEQ ID NO:10, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:11. More preferably, the IL-12 of the present invention preferably is fused human IL-12 (FhIL-12), preferably comprising the amino acid sequence of SEQ ID NO:12, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:13. The terms "polypeptide" and "fusion polypeptide", as used herein, preferably encompass variants of said polypeptides and fusion polypeptides as specified elsewhere herein.
Preferably, the recombinant virus of the family Paramyxoviridae of the present invention further comprises at least one expressible polynucleotide encoding a further activator of the immune response, preferably an immunoglobulin or part thereof, preferably a secreted immunoglobulin.
- 8 -As used herein, the term "further activator of the immune response" relates to a compound which, when contacted with a mixture of immune cells and immune-response inducing cells, e.g. cancer cells, causes at least one type of immune cell to be more active as compared to an immune cell of the same type comprised in the same mixture but lacking said compound. As used herein, the term IL-12 as specified elsewhere herein relates to an activator of the immune response, but not to a further activator of the immune response. Preferably, the immune cell activated is a cell mediating a response increasing a subject's resistance to an antigen, i.e.
preferably, said immune cell is not a tolerance-mediating immune cell.
Preferably, the immune cell activated by the further activator of the immune response is a T-cell, more preferably a helper T-cell or a cytotoxic T-cell. Most preferably, the immune cell activated by the further activator of the immune response is a cytotoxic T-cell expressing PD-1. Measures of immune cell activity are known to the skilled person and include, preferably, expression of activation markers, production of antibodies, excretion of cytokines, and release of cytotoxins, e.g. perforin, granzymes, and/or granolysin.
Preferably, the further activator of the immune response is an antagonist of a signaling pathway causing at least one type of immune cell to become inhibited.
Accordingly, preferably, the further activator of the immune response is a ligand for an immune checkpoint blockade protein. More preferably, the further activator of the immune response is a ligand for an immune checkpoint blockade protein. Still more preferably, the activator of the immune response is an inhibitor of PD-1 receptor signaling. It is understood by the skilled person that signaling through a receptor signaling pathway can be inhibited by either preventing the receptor from being activated, or by preventing the signal generated by the activated receptor from being further transmitted. Accordingly, preferably, the further activator of the immune response is a PD-Li antagonist, the term "antagonist" relating to a compound binding to the molecule the effect of which is antagonized and through said binding preventing said molecule from interacting with its native binding partner in a productive, i.e. signaling-inducing, way. Preferred assays for said activity are described e.g. in WO
2015/128313 Al.
preferably, said immune cell is not a tolerance-mediating immune cell.
Preferably, the immune cell activated by the further activator of the immune response is a T-cell, more preferably a helper T-cell or a cytotoxic T-cell. Most preferably, the immune cell activated by the further activator of the immune response is a cytotoxic T-cell expressing PD-1. Measures of immune cell activity are known to the skilled person and include, preferably, expression of activation markers, production of antibodies, excretion of cytokines, and release of cytotoxins, e.g. perforin, granzymes, and/or granolysin.
Preferably, the further activator of the immune response is an antagonist of a signaling pathway causing at least one type of immune cell to become inhibited.
Accordingly, preferably, the further activator of the immune response is a ligand for an immune checkpoint blockade protein. More preferably, the further activator of the immune response is a ligand for an immune checkpoint blockade protein. Still more preferably, the activator of the immune response is an inhibitor of PD-1 receptor signaling. It is understood by the skilled person that signaling through a receptor signaling pathway can be inhibited by either preventing the receptor from being activated, or by preventing the signal generated by the activated receptor from being further transmitted. Accordingly, preferably, the further activator of the immune response is a PD-Li antagonist, the term "antagonist" relating to a compound binding to the molecule the effect of which is antagonized and through said binding preventing said molecule from interacting with its native binding partner in a productive, i.e. signaling-inducing, way. Preferred assays for said activity are described e.g. in WO
2015/128313 Al.
- 9 -Preferably, the further activator of the immune response is an antagonist as described above selected from the list of molecule types consisting of a peptide aptamer, an anticalin, a Designed Ankyrin Repeat Protein (DARPin), an inhibitory peptide, and, preferably, an immunoglobulin, more preferably, an antibody.
In the context of this invention, a "peptide aptamer" is a peptide specifically binding its interaction partner and having the activity of activating the immune response as specified herein above, preferably, the activity of being an antagonist of PD-Li as specified herein above. Peptide aptamers, preferably, are peptides comprising 8-80 amino acids, more preferably 10-50 amino acids, and most preferably 15-30 amino acids. They can e.g. be isolated from randomized peptide expression libraries in a suitable host system like baker's yeast (see, for example, Klevenz et al., Cell Mol Life Sci. 2002, 59: 1993-1998). A peptide aptamer, preferably, is a free peptide; it is, however, also contemplated by the present invention that a peptide aptamer is fused to a polypeptide serving as "scaffold", meaning that the covalent linking to said polypeptide serves to fix the three-dimensional structure of said peptide aptamer to one specific conformation. More preferably, the peptide aptamer is fused to a transport signal, in particular a peptide export signal.
As used herein, the term "anticalin" relates to an artificial polypeptide derived from a lipocalin specifically binding its interaction partner. Similarly, a "Designed Ankyrin Repeat Protein" or "DARPin", as used herein, is an artificial polypeptide comprising several ankyrin repeat motifs and specifically binding its interaction partner. The anticalins and the DARPins of the present invention have the activity of activating the immune response as specified herein above, preferably, the activity of being an antagonist of PD-L1 as specified herein above.
As used herein, the term "inhibitory peptide" relates to any chemical molecule comprising at least one peptide having the activity of activating the immune response as specified herein above, preferably, the activity of being an antagonist PD-L1 as specified herein above.
Preferably, the inhibitory peptide comprises a peptide having an amino acid sequence corresponding to an amino acid sequence of at least five, at least six, at least seven, at least
In the context of this invention, a "peptide aptamer" is a peptide specifically binding its interaction partner and having the activity of activating the immune response as specified herein above, preferably, the activity of being an antagonist of PD-Li as specified herein above. Peptide aptamers, preferably, are peptides comprising 8-80 amino acids, more preferably 10-50 amino acids, and most preferably 15-30 amino acids. They can e.g. be isolated from randomized peptide expression libraries in a suitable host system like baker's yeast (see, for example, Klevenz et al., Cell Mol Life Sci. 2002, 59: 1993-1998). A peptide aptamer, preferably, is a free peptide; it is, however, also contemplated by the present invention that a peptide aptamer is fused to a polypeptide serving as "scaffold", meaning that the covalent linking to said polypeptide serves to fix the three-dimensional structure of said peptide aptamer to one specific conformation. More preferably, the peptide aptamer is fused to a transport signal, in particular a peptide export signal.
As used herein, the term "anticalin" relates to an artificial polypeptide derived from a lipocalin specifically binding its interaction partner. Similarly, a "Designed Ankyrin Repeat Protein" or "DARPin", as used herein, is an artificial polypeptide comprising several ankyrin repeat motifs and specifically binding its interaction partner. The anticalins and the DARPins of the present invention have the activity of activating the immune response as specified herein above, preferably, the activity of being an antagonist of PD-L1 as specified herein above.
As used herein, the term "inhibitory peptide" relates to any chemical molecule comprising at least one peptide having the activity of activating the immune response as specified herein above, preferably, the activity of being an antagonist PD-L1 as specified herein above.
Preferably, the inhibitory peptide comprises a peptide having an amino acid sequence corresponding to an amino acid sequence of at least five, at least six, at least seven, at least
- 10 -eight, at least nine, at least ten, at least eleven, at least twelve, at least 13, at least 14, or at least 15 consecutive amino acids comprised in a PD-Li polypeptide. Preferably, the inhibitory peptide comprises a peptide having an amino acid sequence corresponding to an amino acid sequence of 5 to 200, more preferably 6 to 100, even more preferably 7 to 50, or, most preferably, 8 to 30 consecutive amino acids comprised in a PD-Li polypeptide.
Moreover, also encompassed are variants of the aforementioned inhibitory peptides. Such variants have at least the same essential biological activity as the specific inhibitory peptides.
As used herein, the term "immunoglobulin" relates to a polypeptide being a soluble immunoglobulin, preferably an antibody from any of the classes IgA, IgD, IgE, IgG, or IgM, preferably having the activity of binding, more preferably specifically binding, a molecule of interest. Immunoglobulins against antigens of interest can be prepared by well known methods using, e.g., a purified molecule of interest or a suitable fragment derived therefrom as an antigen. A fragment which is suitable as an antigen may be identified by antigenicity determining algorithms well known in the art. Such fragments may be obtained either from one of the molecules of interest by proteolytic digestion, may be a synthetic peptide, or may be obtained by recombinant expression. Preferably, a peptide of a molecule of interest used as an antigen is located at the exterior of a cell expressing the molecule of interest; i.e.
preferably, the epitope the binding domain interacts with, preferably, is an extracellular domain. Preferably, the immunoglobulin of the present invention is a monoclonal antibody, a human or humanized antibody or primatized, chimerized antibody or a fragment thereof, so long as they exhibit the desired binding activity as specified elsewhere herein. Also comprised as antibodies of the present invention are a bispecific antibody, a synthetic antibody, or a chemically modified derivative of any of these. Preferably, the antibody of the present invention shall specifically bind (i.e. does only to a negligible extent or, preferably, not cross react with other polypeptides or peptides) to a molecule of interest as specified above.
Specific binding can be tested by various well known techniques. Antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988.
Monoclonal antibodies can be prepared by the techniques originally described in Kohler and Milstein, Nature. 1975. 256: 495; and Galfre, Meth. Enzymol. 1981, 73: 3, which comprise the fusion
Moreover, also encompassed are variants of the aforementioned inhibitory peptides. Such variants have at least the same essential biological activity as the specific inhibitory peptides.
As used herein, the term "immunoglobulin" relates to a polypeptide being a soluble immunoglobulin, preferably an antibody from any of the classes IgA, IgD, IgE, IgG, or IgM, preferably having the activity of binding, more preferably specifically binding, a molecule of interest. Immunoglobulins against antigens of interest can be prepared by well known methods using, e.g., a purified molecule of interest or a suitable fragment derived therefrom as an antigen. A fragment which is suitable as an antigen may be identified by antigenicity determining algorithms well known in the art. Such fragments may be obtained either from one of the molecules of interest by proteolytic digestion, may be a synthetic peptide, or may be obtained by recombinant expression. Preferably, a peptide of a molecule of interest used as an antigen is located at the exterior of a cell expressing the molecule of interest; i.e.
preferably, the epitope the binding domain interacts with, preferably, is an extracellular domain. Preferably, the immunoglobulin of the present invention is a monoclonal antibody, a human or humanized antibody or primatized, chimerized antibody or a fragment thereof, so long as they exhibit the desired binding activity as specified elsewhere herein. Also comprised as antibodies of the present invention are a bispecific antibody, a synthetic antibody, or a chemically modified derivative of any of these. Preferably, the antibody of the present invention shall specifically bind (i.e. does only to a negligible extent or, preferably, not cross react with other polypeptides or peptides) to a molecule of interest as specified above.
Specific binding can be tested by various well known techniques. Antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988.
Monoclonal antibodies can be prepared by the techniques originally described in Kohler and Milstein, Nature. 1975. 256: 495; and Galfre, Meth. Enzymol. 1981, 73: 3, which comprise the fusion
- 11 -of mouse myeloma cells to spleen cells derived from immunized mammals. As will be understood by the skilled person, a molecule of interest, bound by an immunoglobulin of the present invention, may also be an Fc receptor or a complement protein binding an Fe part of an antibody; accordingly, the immunoglobulin preferably is an Fe domain of an antibody, more preferably a soluble Fe domain of an antibody, most preferably a secreted soluble Fe domain of an antibody. Preferably, said antibody the Fe domain is derived from is an IgG, more preferably an IgG 1 , most preferably a human IgGl. Preferably, the secreted soluble Fe domain comprises the amino acid sequence of SEQ ID NO: 16 or a variant thereof, preferably encoded by the nucleic acid sequence of SEQ ID NO: 17. More preferably, the immunoglobulin is an antagonistic anti-PD-Li antibody, still more preferably comprising the amino acid sequence of SEQ ID NO:2 or a variant thereof, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:3 or a variant thereof.
More preferably, the immunoglobulin is an antagonistic anti-PD-L1 antibody, more preferably comprising the amino acid sequence of SEQ ID NO:2, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:3.
"Immunoglobulin fragments" comprise a portion of an intact immunoglobulin, preferably of an antibody, in an embodiment, comprise the antigen-binding region thereof.
Examples of antibody fragments and fusion proteins of variable regions include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules;
single-domain-antibodies (VHH), also known as nanobodies, and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fe" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen. "Fv" is the minimum antibody fragment which contains a complete antigen-binding site. Preferably, a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In a single-chain Fv (scFv) species, one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric"
structure analogous to that in a two-chain Fv species. It is in this configuration that the three hypervariable regions
More preferably, the immunoglobulin is an antagonistic anti-PD-L1 antibody, more preferably comprising the amino acid sequence of SEQ ID NO:2, preferably encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO:3.
"Immunoglobulin fragments" comprise a portion of an intact immunoglobulin, preferably of an antibody, in an embodiment, comprise the antigen-binding region thereof.
Examples of antibody fragments and fusion proteins of variable regions include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules;
single-domain-antibodies (VHH), also known as nanobodies, and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fe" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen. "Fv" is the minimum antibody fragment which contains a complete antigen-binding site. Preferably, a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In a single-chain Fv (scFv) species, one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric"
structure analogous to that in a two-chain Fv species. It is in this configuration that the three hypervariable regions
- 12 -(HVRs, also referred to as complementarity determining regions (CDRs)) of each variable domain interact to define an antigen-binding site. Collectively, the six HVRs of one scFv confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three HVRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site. The term "diabodies" refers to antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
Diabodies may be bivalent or bispecific. Diabodies are described more fully in, for example, EP 0 404 097; WO 1993/01161; Hudson et al., Nat. Med. 9 (2003) 129-134; and Hollinger et al., PNAS
USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9 (2003) 129-134.
The term "secreted", as used herein, relates to a compound being transferred from the interior of a host cell to the exterior of said host cell by a mechanism intrinsic to said host cell.
Preferably, secretion of a polypeptide or fusion polypeptide is mediated by a, preferably eukaryotic, signal peptide mediating import of said peptide or polypeptide into the lumen of the endoplasmic reticulum and, more preferably, by the absence of retention signals. Signal peptides causing secretion of peptides or polypeptides are known in the art.
Preferably, the signal peptide is an IL-12 signal peptide. Also preferably, the signal peptide is or comprises an Ig leader sequence. More preferably, the signal peptide is or comprises a human Ig leader sequence. Still more preferably, the signal peptide is or comprises a matching leader sequence, i.e. a leader sequence selected from the same Ig kappa subgroup as the variable light chain of the antibody, preferably, of the single-chain antibody.
As used herein, the terms "polypeptide variant" relates to any chemical molecule comprising at least one polypeptide or fusion polypeptide as specified elsewhere herein, having the indicated activity, but differing in primary structure from said polypeptide or fusion polypeptide indicated above. Thus, the polypeptide variant, preferably, is a mutein having the
Diabodies may be bivalent or bispecific. Diabodies are described more fully in, for example, EP 0 404 097; WO 1993/01161; Hudson et al., Nat. Med. 9 (2003) 129-134; and Hollinger et al., PNAS
USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9 (2003) 129-134.
The term "secreted", as used herein, relates to a compound being transferred from the interior of a host cell to the exterior of said host cell by a mechanism intrinsic to said host cell.
Preferably, secretion of a polypeptide or fusion polypeptide is mediated by a, preferably eukaryotic, signal peptide mediating import of said peptide or polypeptide into the lumen of the endoplasmic reticulum and, more preferably, by the absence of retention signals. Signal peptides causing secretion of peptides or polypeptides are known in the art.
Preferably, the signal peptide is an IL-12 signal peptide. Also preferably, the signal peptide is or comprises an Ig leader sequence. More preferably, the signal peptide is or comprises a human Ig leader sequence. Still more preferably, the signal peptide is or comprises a matching leader sequence, i.e. a leader sequence selected from the same Ig kappa subgroup as the variable light chain of the antibody, preferably, of the single-chain antibody.
As used herein, the terms "polypeptide variant" relates to any chemical molecule comprising at least one polypeptide or fusion polypeptide as specified elsewhere herein, having the indicated activity, but differing in primary structure from said polypeptide or fusion polypeptide indicated above. Thus, the polypeptide variant, preferably, is a mutein having the
- 13 -indicated activity. Preferably, the polypeptide variant comprises a peptide having an amino acid sequence corresponding to an amino acid sequence of 5 to 200, more preferably 6 to 100, even more preferably 7 to 50, or, most preferably, 8 to 30 consecutive amino acids comprised in a polypeptide as specified above. Moreover, also encompassed are further polypeptide variants of the aforementioned polypeptides. Such polypeptide variants have at least essentially the same biological activity as the specific polypeptides.
Moreover, it is to be understood that a polypeptide variant as referred to in accordance with the present invention shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and/or addition, wherein the amino acid sequence of the variant is still, preferably, at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% identical with the amino acid sequence of the specific polypeptide. The degree of identity between two amino acid sequences can be determined by algorithms well known in the art.
Preferably, the degree of identity is to be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the sequence it is compared to for optimal alignment. The percentage is calculated by determining, preferably over the whole length of the polypeptide, the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981), by the homology alignment algorithm of Needleman and Wunsch (1970), by the search for similarity method of Pearson and Lipman (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, PASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used. Polypeptide variants referred to herein may be allelic variants or any other species specific homologs, paralogs, or orthologs.
Moreover, the polypeptide variants referred to herein include fragments of the specific
Moreover, it is to be understood that a polypeptide variant as referred to in accordance with the present invention shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and/or addition, wherein the amino acid sequence of the variant is still, preferably, at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% identical with the amino acid sequence of the specific polypeptide. The degree of identity between two amino acid sequences can be determined by algorithms well known in the art.
Preferably, the degree of identity is to be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the sequence it is compared to for optimal alignment. The percentage is calculated by determining, preferably over the whole length of the polypeptide, the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981), by the homology alignment algorithm of Needleman and Wunsch (1970), by the search for similarity method of Pearson and Lipman (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, PASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used. Polypeptide variants referred to herein may be allelic variants or any other species specific homologs, paralogs, or orthologs.
Moreover, the polypeptide variants referred to herein include fragments of the specific
- 14 -polypeptides or the aforementioned types of polypeptide variants as long as these fragments and/or variants have the biological activity as referred to above. Such fragments may be or be derived from, e.g., degradation products or splice variants of the polypeptides. Further included are variants which differ due to posttranslational modifications such as phosphorylation, glycosylation, ubiquitinylation, sumoylation, or myristylation, by including non-natural amino acids, and/or by being peptidomimetics.
The term "expressible polynucleotide", as used herein, relates to a polynucleotide operatively linked to at least one expression control sequence causing transcription of the nucleic acid sequence comprised in said polynucleotide to occur, preferably in eukaryotic cells or isolated fractions thereof, preferably into a translatable mRNA or into a viral genome.
Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known in the art. They, preferably, comprise regulatory sequences ensuring initiation of transcription and, optionally, poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers. Preferably, the aforesaid at least one expression control sequence is an expression control sequence of a (-)strand RNA virus, more preferably of a Paramyxovirus as described herein above, most preferably of an MV. Thus, preferably, at least one expression control sequence comprises a (-)strand RNA viral regulatory sequence ensuring initiation of transcription (consensus "gene start signal", preferably consensus MV "gene start signal") and termination signals (consensus "gene stop signal", preferably, consensus MV
"gene stop signal") ensuring termination of transcription and stabilization of the transcript. It is known in the art that production of viral particles in permissive host cells can be initiated by transfecting into said permissive host cells one or more expressible DNA
constructs encoding (i) a recombinant viral anti-genome, (ii) the viral L gene, (iii) the viral P
gene, and (iv) the viral N gene. It is also understood by the skilled person that, once a viral genome and the aforesaid viral genes were expressed in said host cell, replication and assembly of viral particles occurs in the cytoplasm of the host cell and is, therefore, solely dependent on viral regulatory signals. The term polynucleotide, as used herein, preferably encompasses polynucleotide variants as specified elsewhere herein. Preferably, the expressible polynucleotide encoding an IL-12 is comprised in the genome of the recombinant virus of the
The term "expressible polynucleotide", as used herein, relates to a polynucleotide operatively linked to at least one expression control sequence causing transcription of the nucleic acid sequence comprised in said polynucleotide to occur, preferably in eukaryotic cells or isolated fractions thereof, preferably into a translatable mRNA or into a viral genome.
Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known in the art. They, preferably, comprise regulatory sequences ensuring initiation of transcription and, optionally, poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers. Preferably, the aforesaid at least one expression control sequence is an expression control sequence of a (-)strand RNA virus, more preferably of a Paramyxovirus as described herein above, most preferably of an MV. Thus, preferably, at least one expression control sequence comprises a (-)strand RNA viral regulatory sequence ensuring initiation of transcription (consensus "gene start signal", preferably consensus MV "gene start signal") and termination signals (consensus "gene stop signal", preferably, consensus MV
"gene stop signal") ensuring termination of transcription and stabilization of the transcript. It is known in the art that production of viral particles in permissive host cells can be initiated by transfecting into said permissive host cells one or more expressible DNA
constructs encoding (i) a recombinant viral anti-genome, (ii) the viral L gene, (iii) the viral P
gene, and (iv) the viral N gene. It is also understood by the skilled person that, once a viral genome and the aforesaid viral genes were expressed in said host cell, replication and assembly of viral particles occurs in the cytoplasm of the host cell and is, therefore, solely dependent on viral regulatory signals. The term polynucleotide, as used herein, preferably encompasses polynucleotide variants as specified elsewhere herein. Preferably, the expressible polynucleotide encoding an IL-12 is comprised in the genome of the recombinant virus of the
- 15 -family Paramyxoviridae in a region corresponding to the region intervening the P and the M
gene of measles virus.
The term "polynucleotide encoding a recombinant virus", as used herein, relates to a polynucleotide comprising a nucleic acid sequence or nucleic acid sequences required for generating a virus particle or a virus-like particle in a host cell. It is understood by the skilled person that a virus is constituted by a polynucleotide genome and at least one kind of capsid polypeptide. Accordingly, the polynucleotide encoding a recombinant virus of the present invention, preferably, comprises a recombinant virus genome. As will be understood by the skilled person, in case the polynucleotide encoding a recombinant virus is comprised in a virus according to the present invention, i.e. a virus of the family Paramyxoviridae, the polynucleotide is (-)strand RNA. It is also understood by the skilled person that in case the polynucleotide is DNA comprised in a host cell, at least an RNA-dependent RNA
polymerase activity will additionally be required to produce viral particles from said DNA polynucleotide.
Preferably, the polynucleotide encoding a recombinant virus comprises or consists of the nucleic acid sequence as specified elsewhere herein. As annotated herein, the sequence of the DNA copy of negative-strand (-)RNA viruses is annotated in the usual 5' ¨>3'-orientation; this corresponds to the viral sequence in antigenomic (+)RNA orientation with respect to the natural 3'¨*5' -orientation of negative-strand (-)RNA viruses.
The term "polynucleotide variant", as used herein, relates to a variant of a polynucleotide related to herein comprising a nucleic acid sequence characterized in that the sequence can be derived from the aforementioned specific nucleic acid sequence by at least one nucleotide substitution, addition and/or deletion, wherein the polynucleotide variant shall have the activity as specified for the specific polynucleotide. Preferably, said polynucleotide variant is an ortholog, a paralog or another homolog of the specific polynucleotide. Also preferably, said polynucleotide variant is a naturally occurring allele of the specific polynucleotide.
Polynucleotide variants also encompass polynucleotides comprising a nucleic acid sequence which is capable of hybridizing to the aforementioned specific polynucleotides, preferably, under stringent hybridization conditions. These stringent conditions are known to the skilled worker and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.
gene of measles virus.
The term "polynucleotide encoding a recombinant virus", as used herein, relates to a polynucleotide comprising a nucleic acid sequence or nucleic acid sequences required for generating a virus particle or a virus-like particle in a host cell. It is understood by the skilled person that a virus is constituted by a polynucleotide genome and at least one kind of capsid polypeptide. Accordingly, the polynucleotide encoding a recombinant virus of the present invention, preferably, comprises a recombinant virus genome. As will be understood by the skilled person, in case the polynucleotide encoding a recombinant virus is comprised in a virus according to the present invention, i.e. a virus of the family Paramyxoviridae, the polynucleotide is (-)strand RNA. It is also understood by the skilled person that in case the polynucleotide is DNA comprised in a host cell, at least an RNA-dependent RNA
polymerase activity will additionally be required to produce viral particles from said DNA polynucleotide.
Preferably, the polynucleotide encoding a recombinant virus comprises or consists of the nucleic acid sequence as specified elsewhere herein. As annotated herein, the sequence of the DNA copy of negative-strand (-)RNA viruses is annotated in the usual 5' ¨>3'-orientation; this corresponds to the viral sequence in antigenomic (+)RNA orientation with respect to the natural 3'¨*5' -orientation of negative-strand (-)RNA viruses.
The term "polynucleotide variant", as used herein, relates to a variant of a polynucleotide related to herein comprising a nucleic acid sequence characterized in that the sequence can be derived from the aforementioned specific nucleic acid sequence by at least one nucleotide substitution, addition and/or deletion, wherein the polynucleotide variant shall have the activity as specified for the specific polynucleotide. Preferably, said polynucleotide variant is an ortholog, a paralog or another homolog of the specific polynucleotide. Also preferably, said polynucleotide variant is a naturally occurring allele of the specific polynucleotide.
Polynucleotide variants also encompass polynucleotides comprising a nucleic acid sequence which is capable of hybridizing to the aforementioned specific polynucleotides, preferably, under stringent hybridization conditions. These stringent conditions are known to the skilled worker and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.
- 16 -Y. (1989), 6.3.1-6.3.6. A preferred example for stringent hybridization conditions are hybridization conditions in 6x sodium chloride/sodium citrate (= SSC) at approximately 45 C, followed by one or more wash steps in 0.2x SSC, 0.1% SDS at 50 to 65 C. The skilled worker knows that these hybridization conditions differ depending on the type of nucleic acid and, for example when organic solvents are present, with regard to the temperature and concentration of the buffer. For example, under "standard hybridization conditions" the temperature differs depending on the type of nucleic acid between 42 C and 58 C in aqueous buffer with a concentration of 0.1x to 5x SSC (pH 7.2). If organic solvent is present in the abovementioned buffer, for example 50% formamide, the temperature under standard conditions is approximately 42 C. The hybridization conditions for DNA:DNA hybrids are preferably for example 0.1x SSC and 20 C to 45 C, preferably between 30 C and 45 C. The hybridization conditions for DNA:RNA hybrids are preferably, for example, 0.1x SSC and 30 C
to 55 C, preferably between 45 C and 55 C. The abovementioned hybridization temperatures are determined for example for a nucleic acid with approximately 100 bp (= base pairs) in length and a G + C content of 50% in the absence of formamide. The skilled worker knows how to determine the hybridization conditions required by referring to textbooks such as the textbook mentioned above, or the following textbooks: Sambrook et al., "Molecular Cloning", Cold Spring Harbor Laboratory, 1989; Hames and Higgins (Ed.) 1985, "Nucleic Acids Hybridization: A Practical Approach", IRL Press at Oxford University Press, Oxford; Brown (Ed.) 1991, "Essential Molecular Biology: A Practical Approach", IRL Press at Oxford University Press, Oxford. Alternatively, polynucleotide variants are obtainable by PCR-based techniques such as mixed oligonucleotide primer-based amplification of DNA, i.e. using degenerated primers against conserved domains of a polypeptide of the present invention.
Conserved domains of a polypeptide may be identified by a sequence comparison of the nucleic acid sequence of the polynucleotide or the amino acid sequence of the polypeptide of the present invention with sequences of other organisms. As a template, DNA or cDNA from bacteria, fungi, or plants preferably, from animals may be used. Further, variants include polynucleotides comprising nucleic acid sequences which are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical to the specifically indicated nucleic acid sequences. Moreover, also encompassed are polynucleotides which comprise nucleic acid sequences encoding amino acid sequences
to 55 C, preferably between 45 C and 55 C. The abovementioned hybridization temperatures are determined for example for a nucleic acid with approximately 100 bp (= base pairs) in length and a G + C content of 50% in the absence of formamide. The skilled worker knows how to determine the hybridization conditions required by referring to textbooks such as the textbook mentioned above, or the following textbooks: Sambrook et al., "Molecular Cloning", Cold Spring Harbor Laboratory, 1989; Hames and Higgins (Ed.) 1985, "Nucleic Acids Hybridization: A Practical Approach", IRL Press at Oxford University Press, Oxford; Brown (Ed.) 1991, "Essential Molecular Biology: A Practical Approach", IRL Press at Oxford University Press, Oxford. Alternatively, polynucleotide variants are obtainable by PCR-based techniques such as mixed oligonucleotide primer-based amplification of DNA, i.e. using degenerated primers against conserved domains of a polypeptide of the present invention.
Conserved domains of a polypeptide may be identified by a sequence comparison of the nucleic acid sequence of the polynucleotide or the amino acid sequence of the polypeptide of the present invention with sequences of other organisms. As a template, DNA or cDNA from bacteria, fungi, or plants preferably, from animals may be used. Further, variants include polynucleotides comprising nucleic acid sequences which are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical to the specifically indicated nucleic acid sequences. Moreover, also encompassed are polynucleotides which comprise nucleic acid sequences encoding amino acid sequences
- 17 -which are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid sequences specifically indicated. The percent identity values are, preferably, calculated over the entire amino acid or nucleic acid sequence region. A series of programs based on a variety of algorithms is available to the skilled worker for comparing different sequences. In this context, the algorithms of Needleman and Wunsch or Smith and Waterman give particularly reliable results.
To carry out the sequence alignments, the program PileUp (J. Mol. Evolution., 25, 351-360, 1987, Higgins et al., CABIOS, 5 1989: 151-153) or the programs Gap and BestFit (Needleman and Wunsch (J. Mol. Biol. 48; 443-453 (1970)) and Smith and Waterman (Adv. Appl.
Math. 2;
482-489 (1981))), which are part of the GCG software packet (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711 (1991)), are to be used. The sequence identity values recited above in percent (%) are to be determined, preferably, using the program GAP over the entire sequence region with the following settings: Gap Weight: 50, Length Weight: 3, Average Match: 10.000 and Average Mismatch: 0.000, which, unless otherwise specified, shall always be used as standard settings for sequence alignments.
A polynucleotide comprising a fragment of any of the specifically indicated nucleic acid sequences is also encompassed as a variant polynucleotide of the present invention. The fragment shall still encode a polypeptide or fusion polypeptide which still has the activity as specified. Accordingly, the polypeptide encoded may comprise or consist of the domains of the polypeptide of the present invention conferring the said biological activity. A fragment as meant herein, preferably, comprises at least 50, at least 100, at least 250 or at least 500 consecutive nucleotides of any one of the specific nucleic acid sequences or encodes an amino acid sequence comprising at least 20, at least 30, at least 50, at least 80, at least 100 or at least 150 consecutive amino acids of any one of the specific amino acid sequences.
The polynucleotides of the present invention either consist of, essentially consist of, or comprise the aforementioned nucleic acid sequences. Thus, they may contain further nucleic acid sequences as well. Specifically, the polynucleotides of the present invention may encode fusion proteins wherein one partner of the fusion protein is a polypeptide being encoded by a nucleic acid sequence recited above. Such fusion proteins may comprise as additional part
To carry out the sequence alignments, the program PileUp (J. Mol. Evolution., 25, 351-360, 1987, Higgins et al., CABIOS, 5 1989: 151-153) or the programs Gap and BestFit (Needleman and Wunsch (J. Mol. Biol. 48; 443-453 (1970)) and Smith and Waterman (Adv. Appl.
Math. 2;
482-489 (1981))), which are part of the GCG software packet (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711 (1991)), are to be used. The sequence identity values recited above in percent (%) are to be determined, preferably, using the program GAP over the entire sequence region with the following settings: Gap Weight: 50, Length Weight: 3, Average Match: 10.000 and Average Mismatch: 0.000, which, unless otherwise specified, shall always be used as standard settings for sequence alignments.
A polynucleotide comprising a fragment of any of the specifically indicated nucleic acid sequences is also encompassed as a variant polynucleotide of the present invention. The fragment shall still encode a polypeptide or fusion polypeptide which still has the activity as specified. Accordingly, the polypeptide encoded may comprise or consist of the domains of the polypeptide of the present invention conferring the said biological activity. A fragment as meant herein, preferably, comprises at least 50, at least 100, at least 250 or at least 500 consecutive nucleotides of any one of the specific nucleic acid sequences or encodes an amino acid sequence comprising at least 20, at least 30, at least 50, at least 80, at least 100 or at least 150 consecutive amino acids of any one of the specific amino acid sequences.
The polynucleotides of the present invention either consist of, essentially consist of, or comprise the aforementioned nucleic acid sequences. Thus, they may contain further nucleic acid sequences as well. Specifically, the polynucleotides of the present invention may encode fusion proteins wherein one partner of the fusion protein is a polypeptide being encoded by a nucleic acid sequence recited above. Such fusion proteins may comprise as additional part
- 18 -polypeptides for monitoring expression (e.g., green, yellow, blue or red fluorescent proteins, alkaline phosphatase and the like) or so called "tags" which may serve as a detectable marker or as an auxiliary measure for purification purposes. Tags for the different purposes are well known in the art and are described elsewhere herein.
The polynucleotide of the present invention shall be provided, preferably, either as an isolated polynucleotide (i.e. isolated from its natural context) or in genetically modified form. The polynucleotide, preferably, is DNA, including cDNA, or RNA. The term encompasses single as well as double stranded polynucleotides. Moreover, preferably, comprised are also chemically modified polynucleotides including naturally occurring modified polynucleotides such as glycosylated or methylated polynucleotides or artificial modified one such as biotinylated polynucleotides.
As used herein, the term "host cell" relates to a vertebrate cell. Preferably, the cell is a mammalian cell, more preferably, a mouse, rat, cat, dog, hamster, guinea pig, sheep, goat, pig, cattle, or horse cell. Still more preferably, the host cell is a primate cell.
Most preferably, the host cell is a human cell. Preferably, the host cell is a tumor cell, more preferably a cancer cell.
Advantageously, it was found in the work underlying the present invention that oncolytic measles virus can be engineered to express IL-12, in particular an IL-12 fusion polypeptide, while infecting cancer cells and that IL-12 expression strongly enhances the immune response induced by the measles virus against said cancer cells. Moreover, it was found that by further expressing immunoglobulins, in particular an anti-PD-Li antibody, measles virus can further augment the immunological response to cancer cells, thus further contributing to their elimination..
The definitions made above apply mutatis mutandis to the following. Additional definitions and explanations made further below also apply for all embodiments described in this specification mutatis mutandis.
The polynucleotide of the present invention shall be provided, preferably, either as an isolated polynucleotide (i.e. isolated from its natural context) or in genetically modified form. The polynucleotide, preferably, is DNA, including cDNA, or RNA. The term encompasses single as well as double stranded polynucleotides. Moreover, preferably, comprised are also chemically modified polynucleotides including naturally occurring modified polynucleotides such as glycosylated or methylated polynucleotides or artificial modified one such as biotinylated polynucleotides.
As used herein, the term "host cell" relates to a vertebrate cell. Preferably, the cell is a mammalian cell, more preferably, a mouse, rat, cat, dog, hamster, guinea pig, sheep, goat, pig, cattle, or horse cell. Still more preferably, the host cell is a primate cell.
Most preferably, the host cell is a human cell. Preferably, the host cell is a tumor cell, more preferably a cancer cell.
Advantageously, it was found in the work underlying the present invention that oncolytic measles virus can be engineered to express IL-12, in particular an IL-12 fusion polypeptide, while infecting cancer cells and that IL-12 expression strongly enhances the immune response induced by the measles virus against said cancer cells. Moreover, it was found that by further expressing immunoglobulins, in particular an anti-PD-Li antibody, measles virus can further augment the immunological response to cancer cells, thus further contributing to their elimination..
The definitions made above apply mutatis mutandis to the following. Additional definitions and explanations made further below also apply for all embodiments described in this specification mutatis mutandis.
- 19 -The present invention further relates to a polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to the present invention.
The present invention further relates to a host cell comprising the recombinant virus of the family Paramyxoviridae of the present invention and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae of the present invention.
As used herein, the term "host cell" relates to a host cell as specified herein above. Moreover, the host cell comprising the polynucleotide encoding the recombinant virus of the family Paramyxoviridae of the present invention may also be a bacterial, yeast, or insect cell, preferably a bacterial cell of the genus Escherichia, more preferably an Escherichia coli cell.
The present invention also relates to a medicament comprising (a) (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist; (ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention; (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to; or (v) any combination of (i) to (iv); and (b) at least one pharmacologically acceptable excipient.
The terms "medicament" and "pharmaceutical composition", as used herein, relate to the compounds of the present invention and optionally one or more pharmaceutically acceptable carrier, i.e. excipient. The compounds of the present invention can be formulated as pharmaceutically acceptable salts. Acceptable salts comprise acetate, methyl ester, HC1, sulfate, chloride and the like. The pharmaceutical compositions are, preferably, administered locally, topically or systemically. Suitable routes of administration conventionally used for drug administration are oral, intravenous, or parenteral administration as well as inhalation. A
preferred route of administration is intra-tumoral administration. However, depending on the
The present invention further relates to a host cell comprising the recombinant virus of the family Paramyxoviridae of the present invention and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae of the present invention.
As used herein, the term "host cell" relates to a host cell as specified herein above. Moreover, the host cell comprising the polynucleotide encoding the recombinant virus of the family Paramyxoviridae of the present invention may also be a bacterial, yeast, or insect cell, preferably a bacterial cell of the genus Escherichia, more preferably an Escherichia coli cell.
The present invention also relates to a medicament comprising (a) (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist; (ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention; (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to; or (v) any combination of (i) to (iv); and (b) at least one pharmacologically acceptable excipient.
The terms "medicament" and "pharmaceutical composition", as used herein, relate to the compounds of the present invention and optionally one or more pharmaceutically acceptable carrier, i.e. excipient. The compounds of the present invention can be formulated as pharmaceutically acceptable salts. Acceptable salts comprise acetate, methyl ester, HC1, sulfate, chloride and the like. The pharmaceutical compositions are, preferably, administered locally, topically or systemically. Suitable routes of administration conventionally used for drug administration are oral, intravenous, or parenteral administration as well as inhalation. A
preferred route of administration is intra-tumoral administration. However, depending on the
- 20 -nature and mode of action of a compound, the pharmaceutical compositions may be administered by other routes as well. For example, polynucleotide compounds may be administered in a gene therapy approach by using viral vectors or viruses or liposomes.
Moreover, the compounds can be administered in combination with other drugs either in a common pharmaceutical composition or as separated pharmaceutical compositions wherein said separated pharmaceutical compositions may be provided in form of a kit of parts. The compounds are, preferably, administered in conventional dosage forms prepared by combining the drugs with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
The excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and being not deleterious to the recipient thereof The excipient employed may be, for example, a solid, a gel or a liquid carrier. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are phosphate buffered saline solution, syrup, oil such as peanut oil and olive oil, water, emulsions, various types of wetting agents, sterile solutions and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
Said suitable carriers comprise those mentioned above and others well known in the art, see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. The diluent(s) is/are selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, non-immunogenic stabilizers and the like.
Moreover, the compounds can be administered in combination with other drugs either in a common pharmaceutical composition or as separated pharmaceutical compositions wherein said separated pharmaceutical compositions may be provided in form of a kit of parts. The compounds are, preferably, administered in conventional dosage forms prepared by combining the drugs with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
The excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and being not deleterious to the recipient thereof The excipient employed may be, for example, a solid, a gel or a liquid carrier. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are phosphate buffered saline solution, syrup, oil such as peanut oil and olive oil, water, emulsions, various types of wetting agents, sterile solutions and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
Said suitable carriers comprise those mentioned above and others well known in the art, see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. The diluent(s) is/are selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, non-immunogenic stabilizers and the like.
- 21 -A therapeutically effective dose refers to an amount of the compounds to be used in a pharmaceutical composition of the present invention which prevents, ameliorates or treats the symptoms accompanying a disease or condition referred to in this specification. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
The dosage regimen will be determined by the attending physician and other clinical factors;
preferably in accordance with any one of the above described methods. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
Progress can be monitored by periodic assessment. A typical dose can be, for example, in the range of 1 to 1000 lig for a polypeptide or polynucleotide, or 104-108 viral particles for a virus or a virus-like particle; however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. Progress can be monitored by periodic assessment. The pharmaceutical compositions and formulations referred to herein are administered at least once in order to treat or ameliorate or prevent a disease or condition recited in this specification. However, the said pharmaceutical compositions may be administered more than one time, for example from one to four times daily up to a non-limited number of days. Specific pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound referred to herein above in admixture or otherwise associated with a pharmaceutically acceptable carrier or diluent. For making those specific pharmaceutical compositions, the active compound(s) will usually be mixed with a carrier or the diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other suitable containers or vehicles. The resulting formulations are to be adapted to the mode of administration, i.e. in the forms of tablets, capsules, suppositories, solutions, suspensions or the like. Dosage recommendations shall be indicated in the
The dosage regimen will be determined by the attending physician and other clinical factors;
preferably in accordance with any one of the above described methods. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
Progress can be monitored by periodic assessment. A typical dose can be, for example, in the range of 1 to 1000 lig for a polypeptide or polynucleotide, or 104-108 viral particles for a virus or a virus-like particle; however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. Progress can be monitored by periodic assessment. The pharmaceutical compositions and formulations referred to herein are administered at least once in order to treat or ameliorate or prevent a disease or condition recited in this specification. However, the said pharmaceutical compositions may be administered more than one time, for example from one to four times daily up to a non-limited number of days. Specific pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound referred to herein above in admixture or otherwise associated with a pharmaceutically acceptable carrier or diluent. For making those specific pharmaceutical compositions, the active compound(s) will usually be mixed with a carrier or the diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other suitable containers or vehicles. The resulting formulations are to be adapted to the mode of administration, i.e. in the forms of tablets, capsules, suppositories, solutions, suspensions or the like. Dosage recommendations shall be indicated in the
- 22 -prescribers or users instructions in order to anticipate dose adjustments depending on the considered recipient.
Accordingly, the present invention also relates to a method for treating cancer in a subject afflicted with cancer, comprising a) contacting said subject with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), and thereby, b) treating cancer in a subject afflicted with cancer.
The methods of treatment of the present invention, preferably, may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate, e.g., to localizing a tumor and/or diagnosing cancer for step a), or administration of additional medication for step b). Moreover, one or more of said steps may be performed by automated equipment. The method of the present invention, preferably, is an in vivo method of treatment.
The term "treatment" refers to an amelioration of the diseases or disorders referred to herein or the symptoms accompanied therewith to a significant extent. Said treating as used herein also includes an entire restoration of the health with respect to the diseases or disorders referred to herein. It is to be understood that treating as used in accordance with the present invention may not be effective in all subjects to be treated. However, the term shall require
Accordingly, the present invention also relates to a method for treating cancer in a subject afflicted with cancer, comprising a) contacting said subject with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), and thereby, b) treating cancer in a subject afflicted with cancer.
The methods of treatment of the present invention, preferably, may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate, e.g., to localizing a tumor and/or diagnosing cancer for step a), or administration of additional medication for step b). Moreover, one or more of said steps may be performed by automated equipment. The method of the present invention, preferably, is an in vivo method of treatment.
The term "treatment" refers to an amelioration of the diseases or disorders referred to herein or the symptoms accompanied therewith to a significant extent. Said treating as used herein also includes an entire restoration of the health with respect to the diseases or disorders referred to herein. It is to be understood that treating as used in accordance with the present invention may not be effective in all subjects to be treated. However, the term shall require
- 23 -that, preferably, a statistically significant portion of subjects suffering from a disease or disorder referred to herein can be successfully treated. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc.. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99 %. The p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001. Preferably, the treatment shall be effective for at least 10%, at least 20% at least 50%at least 60%, at least 70%, at least 80%, or at least 90% of the subjects of a given cohort or population. Preferably, treating cancer is reducing tumor burden in a subject. As will be understood by the skilled person, effectiveness of treatment of e.g. cancer is dependent on a variety of factors including, e.g. cancer stage and cancer type.
As used herein, the term "subject" relates to a vertebrate. Preferably, the subject is a mammal, more preferably, a mouse, rat, cat, dog, hamster, guinea pig, sheep, goat, pig, cattle, or horse.
Still more preferably, the subject is a primate. Most preferably, the subject is a human.
Preferably, the subject is afflicted with a disease caused or aggravated by an insufficient response of the immune response of said subject, more preferably, the subject is afflicted with cancer.
The term "cancer", as used herein, relates to a disease of an animal, including man, characterized by uncontrolled growth by a group of body cells ("cancer cells"). This uncontrolled growth may be accompanied by intrusion into and destruction of surrounding tissue and possibly spread of cancer cells to other locations in the body.
Preferably, also included by the term cancer is a relapse. Thus, preferably, the cancer is a solid cancer, a metastasis, or a relapse thereof.
Preferably, the cancer is selected from the list consisting of acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related lymphoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid, basal cell carcinoma, bile duct cancer, bladder cancer, brain stem glioma, breast cancer, burkitt lymphoma, carcinoid tumor, cerebellar astrocytoma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic
As used herein, the term "subject" relates to a vertebrate. Preferably, the subject is a mammal, more preferably, a mouse, rat, cat, dog, hamster, guinea pig, sheep, goat, pig, cattle, or horse.
Still more preferably, the subject is a primate. Most preferably, the subject is a human.
Preferably, the subject is afflicted with a disease caused or aggravated by an insufficient response of the immune response of said subject, more preferably, the subject is afflicted with cancer.
The term "cancer", as used herein, relates to a disease of an animal, including man, characterized by uncontrolled growth by a group of body cells ("cancer cells"). This uncontrolled growth may be accompanied by intrusion into and destruction of surrounding tissue and possibly spread of cancer cells to other locations in the body.
Preferably, also included by the term cancer is a relapse. Thus, preferably, the cancer is a solid cancer, a metastasis, or a relapse thereof.
Preferably, the cancer is selected from the list consisting of acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related lymphoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid, basal cell carcinoma, bile duct cancer, bladder cancer, brain stem glioma, breast cancer, burkitt lymphoma, carcinoid tumor, cerebellar astrocytoma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic
- 24 -myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hodgkin lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway glioma, intraocular melanoma, kaposi sarcoma, laryngeal cancer, medulloblastoma, medulloepithelioma, melanoma, merkel cell carcinoma, mesothelioma, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sezary syndrome, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer, testicular cancer, throat cancer, thymic carcinoma, thymoma, thyroid cancer, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, waldenstrom macroglobulinemia, and wilms tumor. More preferably, the cancer is a solid cancer, a metastasis, or a relapse thereof Most preferably, the cancer is a tumor derived from malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.
Preferably, the method of treatment of the present invention comprises contacting a subject with a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist. Thus, preferably, the method comprises contacting a subject with a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12, wherein said recombinant virus of the family Paramyxoviridae is not a virus disclosed
Preferably, the method of treatment of the present invention comprises contacting a subject with a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist. Thus, preferably, the method comprises contacting a subject with a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12, wherein said recombinant virus of the family Paramyxoviridae is not a virus disclosed
- 25 -in WO 2015/128313 Al. Preferably, said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide and not comprising an expressible polynucleotide encoding a ligand for an immune checkpoint blockade protein.
More preferably, the recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide as the only expressible polynucleotide encoding an activator of the immune response, i. e. preferably, the recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 does not comprise an expressible polynucleotide encoding a further activator of the immune response.
The present invention further relates to an in vitro method for activating immune cells with antitumor activity in a sample comprising cancer cells and immune cells, comprising a) contacting said sample comprising cancer cells and immune cells with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Ll antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), and thereby, b) activating immune cells with antitumor activity comprised in said sample..
The method for activating immune cells with antitumor activity may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate, e.g., to providing the recombinant virus of the family Paramyxoviridae for step a), administering
More preferably, the recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide as the only expressible polynucleotide encoding an activator of the immune response, i. e. preferably, the recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 does not comprise an expressible polynucleotide encoding a further activator of the immune response.
The present invention further relates to an in vitro method for activating immune cells with antitumor activity in a sample comprising cancer cells and immune cells, comprising a) contacting said sample comprising cancer cells and immune cells with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Ll antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), and thereby, b) activating immune cells with antitumor activity comprised in said sample..
The method for activating immune cells with antitumor activity may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate, e.g., to providing the recombinant virus of the family Paramyxoviridae for step a), administering
- 26 -further activating compounds, e.g. cytokines, to the immune cells in step b), or separating immune cells from cancer cells after step b). Moreover, one or more of said steps may be performed by automated equipment.
Moreover, the present invention relates to a recombinant virus of the family Paramyxoviridae of the present invention for use in treatment of inappropriate cell proliferation.
The term "inappropriate cell proliferation" relates to any proliferation of cells of a subject which is not appropriate to the physiological state of said subject and/or to the tissue context of said cells. Preferably, inappropriate cell proliferation is caused or aggravated by an inhibition or insufficient activation of the immune system, more preferably inhibition or insufficient activation of T cells. Also preferably, inappropriate cell proliferation is cancer.
The present invention further relates to a kit comprising at least (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), housed in a container.
The term "kit", as used herein, refers to a collection of the aforementioned components.
Preferably, said components are combined with additional components, preferably within an outer container. The outer container, also preferably, comprises instructions for carrying out a
Moreover, the present invention relates to a recombinant virus of the family Paramyxoviridae of the present invention for use in treatment of inappropriate cell proliferation.
The term "inappropriate cell proliferation" relates to any proliferation of cells of a subject which is not appropriate to the physiological state of said subject and/or to the tissue context of said cells. Preferably, inappropriate cell proliferation is caused or aggravated by an inhibition or insufficient activation of the immune system, more preferably inhibition or insufficient activation of T cells. Also preferably, inappropriate cell proliferation is cancer.
The present invention further relates to a kit comprising at least (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), housed in a container.
The term "kit", as used herein, refers to a collection of the aforementioned components.
Preferably, said components are combined with additional components, preferably within an outer container. The outer container, also preferably, comprises instructions for carrying out a
- 27 -method of the present invention. Examples for such the components of the kit as well as methods for their use have been given in this specification. The kit, preferably, contains the aforementioned components in a ready-to-use formulation. Preferably, the kit may additionally comprise instructions, e.g., a user's manual for applying the recombinant virus of the family Paramyxoviridae with respect to the applications provided by the methods of the present invention. Details are to be found elsewhere in this specification.
Additionally, such user's manual may provide instructions about correctly using the components of the kit. A
user's manual may be provided in paper or electronic form, e.g., stored on CD
or CD ROM.
The present invention also relates to the use of said kit in any of the methods according to the present invention.
Moreover, the present invention relates to a use of (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), for the manufacture of a medicament for treating inappropriate cell proliferation, preferably for treating cancer.
Summarizing the findings of the present invention, the following embodiments are preferred:
Additionally, such user's manual may provide instructions about correctly using the components of the kit. A
user's manual may be provided in paper or electronic form, e.g., stored on CD
or CD ROM.
The present invention also relates to the use of said kit in any of the methods according to the present invention.
Moreover, the present invention relates to a use of (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 fusion polypeptide of the present invention;
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to (iii); or (v) any combination of (i) to (iv), for the manufacture of a medicament for treating inappropriate cell proliferation, preferably for treating cancer.
Summarizing the findings of the present invention, the following embodiments are preferred:
- 28 -1. A
recombinant virus of the family Paramyxoviridae, comprising an expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p40 subunit of an IL-12 and a p35 subunit of an IL-12.
2. The recombinant virus of the family Paramyxoviridae of embodiment 1, wherein said p40 subunit and said p35 subunit of said IL-12 fusion polypeptide are from the same species.
3. The recombinant virus of the family Paramyxoviridae of embodiment 1 or 2, wherein said p40 subunit and said p35 subunit of said IL-12 fusion polypeptide are a mouse p40 subunit and a mouse p35 subunit or a variant thereof, preferably are a human p40 subunit and a human p35 subunit or a variant thereof.
4. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 3, wherein said p40 subunit and said p35 subunit of said IL-12 fusion polypeptide are a mouse p40 subunit and a mouse p35 subunit, preferably are a human p40 subunit and a human p35 subunit.
5. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 4, wherein said IL-12 fusion polypeptide comprises the structure p40-linker-p35.
6. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 5, wherein said linker is -(glycine4-serine)n-, with n=1 to 10, preferably n=2 to 5, more preferably n=3.
7. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 5, wherein said linker is -(glycine6-serine)-.
8. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 7, wherein said expressible polynucleotide encoding an IL-12 is comprised in the genome of the recombinant virus of the family Paramyxoviridae in a region corresponding to the region intervening the P and the M gene of measles virus.
recombinant virus of the family Paramyxoviridae, comprising an expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p40 subunit of an IL-12 and a p35 subunit of an IL-12.
2. The recombinant virus of the family Paramyxoviridae of embodiment 1, wherein said p40 subunit and said p35 subunit of said IL-12 fusion polypeptide are from the same species.
3. The recombinant virus of the family Paramyxoviridae of embodiment 1 or 2, wherein said p40 subunit and said p35 subunit of said IL-12 fusion polypeptide are a mouse p40 subunit and a mouse p35 subunit or a variant thereof, preferably are a human p40 subunit and a human p35 subunit or a variant thereof.
4. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 3, wherein said p40 subunit and said p35 subunit of said IL-12 fusion polypeptide are a mouse p40 subunit and a mouse p35 subunit, preferably are a human p40 subunit and a human p35 subunit.
5. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 4, wherein said IL-12 fusion polypeptide comprises the structure p40-linker-p35.
6. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 5, wherein said linker is -(glycine4-serine)n-, with n=1 to 10, preferably n=2 to 5, more preferably n=3.
7. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 5, wherein said linker is -(glycine6-serine)-.
8. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 7, wherein said expressible polynucleotide encoding an IL-12 is comprised in the genome of the recombinant virus of the family Paramyxoviridae in a region corresponding to the region intervening the P and the M gene of measles virus.
- 29 -9. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 8, further comprising at least one expressible polynucleotide encoding a further activator of the immune response.
10. The recombinant virus of the family Paramyxoviridae of embodiment 9, wherein said further activator of the immune response is an immunoglobulin or fragment thereof.
11. The recombinant virus of the family Paramyxoviridae of embodiments 9 or 10, wherein said further activator of the immune response is a secreted immunoglobulin.
12. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 11, wherein said further activator of the immune response is an Pc domain of an antibody.
13. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 12, wherein said further activator of the immune response is a secreted soluble Fe domain of a human IgG1 antibody.
14. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 13, wherein said further activator of the immune response is a secreted soluble activator of the immune response.
15. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 14, wherein said further activator of the immune response is a single-chain antibody or a nanobody.
16. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 15, wherein said further activator of the immune response is a secreted soluble anti-PD-L1 antibody.
10. The recombinant virus of the family Paramyxoviridae of embodiment 9, wherein said further activator of the immune response is an immunoglobulin or fragment thereof.
11. The recombinant virus of the family Paramyxoviridae of embodiments 9 or 10, wherein said further activator of the immune response is a secreted immunoglobulin.
12. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 11, wherein said further activator of the immune response is an Pc domain of an antibody.
13. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 12, wherein said further activator of the immune response is a secreted soluble Fe domain of a human IgG1 antibody.
14. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 13, wherein said further activator of the immune response is a secreted soluble activator of the immune response.
15. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 14, wherein said further activator of the immune response is a single-chain antibody or a nanobody.
16. The recombinant virus of the family Paramyxoviridae of any one of embodiments 9 to 15, wherein said further activator of the immune response is a secreted soluble anti-PD-L1 antibody.
- 30 -17. The recombinant virus of the family Paramyxoviridae of embodiment 16, wherein said secreted soluble anti-PD-Ll antibody comprises an amino acid sequence according to SEQ ID
NO: 2.
18. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 17, wherein said recombinant virus is a recombinant Morbillivirus, preferably, a recombinant measles virus (MV).
19. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 18, wherein said recombinant MV is derived from MV strain Edmonston A or B, preferably B, more preferably from MV vaccine strain Schwarz/Moraten.
20. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 19, wherein the at least one expressible polynucleotide encoding an IL-12 polypeptide is comprised in a polynucleotide encoding the recombinant virus of the family Paramyxoviridae.
21. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 20, wherein said polynucleotide encoding the recombinant virus of the family Paramyxoviridae comprises the nucleic acid sequence of any one of SEQ ID NOs:
4 to 7, 14, and 15.
22. A polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to any one of embodiments 1 to 21.
23. The polynucleotide according to embodiment 22, wherein said polynucleotide comprises the nucleic acid sequence any one of SEQ ID NOs: 4 to 7, 14, and 15.
24. A host cell comprising the recombinant virus of the family Paramyxoviridae according to any one of embodiments 1 to 21 and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to embodiment 21 or 22.
NO: 2.
18. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 17, wherein said recombinant virus is a recombinant Morbillivirus, preferably, a recombinant measles virus (MV).
19. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 18, wherein said recombinant MV is derived from MV strain Edmonston A or B, preferably B, more preferably from MV vaccine strain Schwarz/Moraten.
20. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 19, wherein the at least one expressible polynucleotide encoding an IL-12 polypeptide is comprised in a polynucleotide encoding the recombinant virus of the family Paramyxoviridae.
21. The recombinant virus of the family Paramyxoviridae of any one of embodiments 1 to 20, wherein said polynucleotide encoding the recombinant virus of the family Paramyxoviridae comprises the nucleic acid sequence of any one of SEQ ID NOs:
4 to 7, 14, and 15.
22. A polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to any one of embodiments 1 to 21.
23. The polynucleotide according to embodiment 22, wherein said polynucleotide comprises the nucleic acid sequence any one of SEQ ID NOs: 4 to 7, 14, and 15.
24. A host cell comprising the recombinant virus of the family Paramyxoviridae according to any one of embodiments 1 to 21 and/or the polynucleotide encoding the recombinant virus of the family Paramyxoviridae according to embodiment 21 or 22.
-31-25. A medicament comprising (a) (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and (b) at least one pharmacologically acceptable excipient.
26. A method for treating cancer in a subject afflicted with cancer, comprising a) contacting said subject with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and, thereby, b) treating cancer in a subject afflicted with cancer.
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and (b) at least one pharmacologically acceptable excipient.
26. A method for treating cancer in a subject afflicted with cancer, comprising a) contacting said subject with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and, thereby, b) treating cancer in a subject afflicted with cancer.
-32 -27. The method of embodiment 26, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide and not comprising an expressible polynucleotide encoding a ligand for an immune checkpoint blockade protein.
28. The method of embodiment 26 or 27, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide as the only expressible polynucleotide encoding an activator of the immune response.
29. The method of any one of embodiments 26 to 28, wherein said cancer is a solid cancer, a metastasis, or a relapse thereof.
30. The method of any one of embodiments 26 to 29, wherein treating cancer is reducing tumor burden.
31. The method of any one of embodiments 26 to 30, wherein said cancer is malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.
32. An in vitro method for activating immune cells with antitumor activity in a sample comprising cancer cells and immune cells, comprising a) contacting said sample comprising cancer cells and immune cells with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii),
28. The method of embodiment 26 or 27, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide as the only expressible polynucleotide encoding an activator of the immune response.
29. The method of any one of embodiments 26 to 28, wherein said cancer is a solid cancer, a metastasis, or a relapse thereof.
30. The method of any one of embodiments 26 to 29, wherein treating cancer is reducing tumor burden.
31. The method of any one of embodiments 26 to 30, wherein said cancer is malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.
32. An in vitro method for activating immune cells with antitumor activity in a sample comprising cancer cells and immune cells, comprising a) contacting said sample comprising cancer cells and immune cells with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii),
- 33 -(iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and thereby, b) activating immune cells with antitumor activity comprised in said sample.
33. Use of (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv);
for the manufacture of a medicament for treating cancer.
33. Use of (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv);
for the manufacture of a medicament for treating cancer.
34. A recombinant virus of the family Paramyxoviridae according to any one of embodiments 1 to 21 and/or a polynucleotide according to embodiment 22 or 23 for use in medical treatment.
35. A recombinant virus of the family Paramyxoviridae (i) comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a antagonist, a CD86 antagonist, or a PD-L1 antagonist; and/or (ii) according of any one of embodiments 1 to 21, for use in treatment of inappropriate cell proliferation.
36. The recombinant virus of the family Paramyxoviridae for use of embodiment 35, wherein treatment of inappropriate cell proliferation is cancer treatment.
37. A kit comprising (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-Li antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv);
housed in a container.
All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.
Figure Legends Fig.1: One step growth curves in Vero-aHis (A) and MC38cea (B) cells: Cells were transduced with MeVac encoding the respective transgenes at M0I=3. Cell suspensions were collected by scraping in the culture medium and titre determined at the depicted time points.
Fig. 2: Cytotoxic effect in the target MC8cea cells: Cells were transduced with MeVac encoding the respective transgenes at MOI-5 and cell viability was determined by XTT assay at the depicted time points. Mean results of triplicate infections per time point with standard errors of the mean (not visible for some data points) are shown.
Fig. 3: Expression of MeVac encoded immunomodulators in MC38cea cells. MC38cea cells were transduced with MeVac encoding the respective immunomodulators and eGFP
or IgGl-Fc as control vectors at MOI=3. Supernatant samples were collected at the depicted time points and transgene expression detected by ELISA. Unspecific binding was controlled by IgG 1 -Fc (upper panels) or eGFP (lower panels) supernatants and subtracted from the specific measurements. In case of mIP-10 an increase of the signal was observed in the eGFP controls which was not subtracted from the specific measurements and is depicted accordingly.
Fig. 4: MeVac encoded anti-PD-Li binding to MC38cea cells. MC38cea cells were incubated with supernatant from Vero-aHis infected with MeVac encoding anti-PD-Li or IgG
1 -Fc. For detection of bound anti-PD-L1, cells were stained with primary Ab specific for HA tag and secondary Ab coupled to PE. DAPI staining was used to exclude dead cells and samples were analyzed by flow cytometry. (A) Overlay histogram for PE of DAPI- MC38cea populations from one of three independent experiments is shown on panel (B). (B)Average median fluorescence intensity (MFI) of PE for DAPI- populations with standard error of the means from the three independent experiments is shown on the left panel.
Fig. 5: Functionality of MeVac encoded immunomodulators. (A) MC38cea cells were treated with supernatants from Vero-aHis cells infected with MeVac encoding the respective immunomodulators and cocultured in ratio 2:1 with murine splenocytes in the presence of PMA and ionomycin in 96-well plate. After 24h the supernatants were collected and IFN-y concentration measured by ELISA. Relative activation corresponds to ratio of the optical density (absorbance at 450nm minus 570nm) of the respective samples to activated splenocytes. Data for one of three independent experiments are shown; (B) splenocytes were stimulated with recombinant murine IL-2 and cultivated in the presence of medium from Vero-aHis infected with MeVac encoding FmIL-12 or eGFP. After 48h the supernatants were collected and IFN-y concentration measured by ELISA. Mean results with standard error of the mean of triplicate splenocyte cultures per FmIL-12 concentration are shown. IFN-y concentration in the eGFP controls was close to background.
Fig. 6: Therapeutic efficacy of immunomodulatory MeVac in vivo: Breaking immunosuppression: MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (6-9 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1 x106 cell infectious units (ciu) with the respective viruses on four consecutive days in 100 JAL Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500mm3 or when ulceration occurred.
Fig. 7: Therapeutic efficacy of immunomodulatory MeVac in vivo: Activating DCs and effector cells: Therapeutic. MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (6-9 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 5x105 ciu with the respective viruses on five consecutive days in 100 111. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 8: Rechallenge of long term survivors with MC38cea. Mice experiencing complete tumor remission in the experiments identifying the most effective MeVac vectors and were rechallenged with MC38cea cells 3 to 6 months after the initinal tumor cell implantation.
Eight naive mice served as a control group. 1x105 MC38cea cells were implanted subcutaneously (s.c.) in the left flank of the mice. Tumor engraftment rates were monitored.
Fig. 9: Comparison of therapeutic efficacy of MeVac encoding FmIL-12 and anti-PD-L 1 .
MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (10 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1x106 ciu with the respective viruses on four consecutive days in 100 1.t1. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 10: Rechallenge of long term survivors from the experiment comparing efficacy of FmIL-12 and anti-PD-Li encoding vectors with MC38cea. Mice were rechallenged with MC38cea cells ca. 6 months after the initinal tumor cell implantation. Ten naive mice served as a control group. 1 x105 MC38cea cells were implanted subcutaneously (s.c.) in the left flank of the mice. Tumor engraftment rates were monitored.
Fig. 11: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 versus MeVac anti-PD-Li efficacy experiment. Anti-tumor:
Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naïve mice were stimulated with recombinant murine IL-2 and cocultivated with MC38cea (A) or MC38 (B) and B16 (B) tumor cells or irrelevant human cell lysate (DLD-1). After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-y concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 12: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 versus MeVac anti-PD-Li efficacy experiment: Anti-MeVac:
Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naïve mice were stimulated with recombinant murine IL-2 and cocultivated with MeVac (A) or as controls with an irrelevant human cell lysate (DLD-1) (B) or as a negative control splenocytes were cultivated alone. After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-7 concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 13: Comparison of therapeutic efficacy of combination of MeVac encoding Fm-IL-12 and anti-PD-L1 with either vector in combination with a control vector encoding IgG 1 -Fc.
MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice
(ii) a recombinant virus of the family Paramyxoviridae according of any one of embodiments 1 to 21, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv);
housed in a container.
All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.
Figure Legends Fig.1: One step growth curves in Vero-aHis (A) and MC38cea (B) cells: Cells were transduced with MeVac encoding the respective transgenes at M0I=3. Cell suspensions were collected by scraping in the culture medium and titre determined at the depicted time points.
Fig. 2: Cytotoxic effect in the target MC8cea cells: Cells were transduced with MeVac encoding the respective transgenes at MOI-5 and cell viability was determined by XTT assay at the depicted time points. Mean results of triplicate infections per time point with standard errors of the mean (not visible for some data points) are shown.
Fig. 3: Expression of MeVac encoded immunomodulators in MC38cea cells. MC38cea cells were transduced with MeVac encoding the respective immunomodulators and eGFP
or IgGl-Fc as control vectors at MOI=3. Supernatant samples were collected at the depicted time points and transgene expression detected by ELISA. Unspecific binding was controlled by IgG 1 -Fc (upper panels) or eGFP (lower panels) supernatants and subtracted from the specific measurements. In case of mIP-10 an increase of the signal was observed in the eGFP controls which was not subtracted from the specific measurements and is depicted accordingly.
Fig. 4: MeVac encoded anti-PD-Li binding to MC38cea cells. MC38cea cells were incubated with supernatant from Vero-aHis infected with MeVac encoding anti-PD-Li or IgG
1 -Fc. For detection of bound anti-PD-L1, cells were stained with primary Ab specific for HA tag and secondary Ab coupled to PE. DAPI staining was used to exclude dead cells and samples were analyzed by flow cytometry. (A) Overlay histogram for PE of DAPI- MC38cea populations from one of three independent experiments is shown on panel (B). (B)Average median fluorescence intensity (MFI) of PE for DAPI- populations with standard error of the means from the three independent experiments is shown on the left panel.
Fig. 5: Functionality of MeVac encoded immunomodulators. (A) MC38cea cells were treated with supernatants from Vero-aHis cells infected with MeVac encoding the respective immunomodulators and cocultured in ratio 2:1 with murine splenocytes in the presence of PMA and ionomycin in 96-well plate. After 24h the supernatants were collected and IFN-y concentration measured by ELISA. Relative activation corresponds to ratio of the optical density (absorbance at 450nm minus 570nm) of the respective samples to activated splenocytes. Data for one of three independent experiments are shown; (B) splenocytes were stimulated with recombinant murine IL-2 and cultivated in the presence of medium from Vero-aHis infected with MeVac encoding FmIL-12 or eGFP. After 48h the supernatants were collected and IFN-y concentration measured by ELISA. Mean results with standard error of the mean of triplicate splenocyte cultures per FmIL-12 concentration are shown. IFN-y concentration in the eGFP controls was close to background.
Fig. 6: Therapeutic efficacy of immunomodulatory MeVac in vivo: Breaking immunosuppression: MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (6-9 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1 x106 cell infectious units (ciu) with the respective viruses on four consecutive days in 100 JAL Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500mm3 or when ulceration occurred.
Fig. 7: Therapeutic efficacy of immunomodulatory MeVac in vivo: Activating DCs and effector cells: Therapeutic. MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (6-9 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 5x105 ciu with the respective viruses on five consecutive days in 100 111. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 8: Rechallenge of long term survivors with MC38cea. Mice experiencing complete tumor remission in the experiments identifying the most effective MeVac vectors and were rechallenged with MC38cea cells 3 to 6 months after the initinal tumor cell implantation.
Eight naive mice served as a control group. 1x105 MC38cea cells were implanted subcutaneously (s.c.) in the left flank of the mice. Tumor engraftment rates were monitored.
Fig. 9: Comparison of therapeutic efficacy of MeVac encoding FmIL-12 and anti-PD-L 1 .
MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (10 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1x106 ciu with the respective viruses on four consecutive days in 100 1.t1. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 10: Rechallenge of long term survivors from the experiment comparing efficacy of FmIL-12 and anti-PD-Li encoding vectors with MC38cea. Mice were rechallenged with MC38cea cells ca. 6 months after the initinal tumor cell implantation. Ten naive mice served as a control group. 1 x105 MC38cea cells were implanted subcutaneously (s.c.) in the left flank of the mice. Tumor engraftment rates were monitored.
Fig. 11: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 versus MeVac anti-PD-Li efficacy experiment. Anti-tumor:
Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naïve mice were stimulated with recombinant murine IL-2 and cocultivated with MC38cea (A) or MC38 (B) and B16 (B) tumor cells or irrelevant human cell lysate (DLD-1). After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-y concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 12: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 versus MeVac anti-PD-Li efficacy experiment: Anti-MeVac:
Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naïve mice were stimulated with recombinant murine IL-2 and cocultivated with MeVac (A) or as controls with an irrelevant human cell lysate (DLD-1) (B) or as a negative control splenocytes were cultivated alone. After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-7 concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 13: Comparison of therapeutic efficacy of combination of MeVac encoding Fm-IL-12 and anti-PD-L1 with either vector in combination with a control vector encoding IgG 1 -Fc.
MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice
- 38 -(8-10 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1x106 ciu with the respective viruses on four consecutive days in 100 l.ti. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 14: Rechallenge of long term survivors from the experiment comparing efficacy of combination of MeVac encoding Fm-IL-12 and anti-PD-Li with either vector in combination with a control vector encoding IgG 1 -Fc. Mice were rechallenged with MC38cea cells ca. 5 months after the initinal tumor cell implantation. Ten naive mice served as a control group.
1 x105 MC38cea cells were implanted subcutaneously (s.c.) in the left flank of the mice.
Tumor engraftment rates were monitored.
Fig. 15: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 and MeVac anti-PD-Li combination experiment: Anti-tumor:
Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naïve mice were stimulated with recombinant murine IL-2 and cocultivated with MC38cea (A), MC38 (B) or B16 (C) tumor cells. After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-y concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 16: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 and MeVac anti-PD-Li combination experiment: Anti-MeVac: Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naive mice were stimulated with recombinant murine IL-2 and cocultivated with MeVac (A) or Vero-aHis lysate (B). After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-y concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 14: Rechallenge of long term survivors from the experiment comparing efficacy of combination of MeVac encoding Fm-IL-12 and anti-PD-Li with either vector in combination with a control vector encoding IgG 1 -Fc. Mice were rechallenged with MC38cea cells ca. 5 months after the initinal tumor cell implantation. Ten naive mice served as a control group.
1 x105 MC38cea cells were implanted subcutaneously (s.c.) in the left flank of the mice.
Tumor engraftment rates were monitored.
Fig. 15: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 and MeVac anti-PD-Li combination experiment: Anti-tumor:
Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naïve mice were stimulated with recombinant murine IL-2 and cocultivated with MC38cea (A), MC38 (B) or B16 (C) tumor cells. After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-y concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
Fig. 16: IFN-y memory recall in murine splenocytes from mice experiencing complete tumor remissions in MeVac FmIL-12 and MeVac anti-PD-Li combination experiment: Anti-MeVac: Freshly isolated splenocytes from mice treated with MeVac encoding the respective immunomodulators or naive mice were stimulated with recombinant murine IL-2 and cocultivated with MeVac (A) or Vero-aHis lysate (B). After 48h of cultivation cell culture medium was collected and IFN-y concentration was measured by ELISA. IFN-y concentrations in the individual cocultures with median in the group (A) or average concentration from two replicate measurements with standard error of the mean (SEM) are shown (B).
- 39 -Fig. 17: Comparison of therapeutic efficacy of combination of MeVac encoding Fm-IL-12 and anti-PD-Li with either vector in combination with a control vector encoding IgG 1 -Fc.
B16-CD20 cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (8-10 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1 x106 ciu with the respective viruses on four consecutive days in 100 111. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 18: Schemes of the constructed recombinant MeVac genomes. A) Transgenes encoding different immunomodulators as well as eGFP and IgG1 -Fc as controls were inserted in different positions of MeVac genome. Murine IL-12 was inserted as a fusion protein consisting of p40 and p35 protein subunits linked by a (Gly4Ser)3 linker (FmIL-12). Murine CD80 was inserted as a soluble form of the protein consisting of the extracellular part of the protein fused to a human IgG 1 -Fc (CD8O-Fc). The MeVac H gene in the novel constructs was fully retargeted to human CEA (hCEA) antigen by ablating attachment to the natural receptors, fusing the H protein to a single chain antibody (scAb) against the hCEA and including a six-histidine tag at the C terminus to allow specific transduction of murine MC38cea cells via human CEA antigen and Vero-aHis cells via anti-His scAb. B) Scheme of MeVac genomes encoding FmIL-12 or anti-PD-Li or IgG 1 -Fc retargeted to human CD20.
MeVac H gene was fully retargeted to human CD20 antigen by ablating attachment to the natural receptors, fusing the H protein to a single chain antibody (scAb) against the CD20 and including a six-histidine tag at the C terminus to allow specific transduction of murine melanoma B16-CD20 cells via human CD20 antigen and Vero-aHis cells via anti-His scAb.
The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.
Examples Example 1: Cell culture
B16-CD20 cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (8-10 animals per group). When tumors reached an average volume of 50 mm3 mice received intratumoral injections with 1 x106 ciu with the respective viruses on four consecutive days in 100 111. Tumor volume was determined every third day and mice were sacrificed when tumor volumes exceeded 1500 mm3 or when ulceration occurred.
Fig. 18: Schemes of the constructed recombinant MeVac genomes. A) Transgenes encoding different immunomodulators as well as eGFP and IgG1 -Fc as controls were inserted in different positions of MeVac genome. Murine IL-12 was inserted as a fusion protein consisting of p40 and p35 protein subunits linked by a (Gly4Ser)3 linker (FmIL-12). Murine CD80 was inserted as a soluble form of the protein consisting of the extracellular part of the protein fused to a human IgG 1 -Fc (CD8O-Fc). The MeVac H gene in the novel constructs was fully retargeted to human CEA (hCEA) antigen by ablating attachment to the natural receptors, fusing the H protein to a single chain antibody (scAb) against the hCEA and including a six-histidine tag at the C terminus to allow specific transduction of murine MC38cea cells via human CEA antigen and Vero-aHis cells via anti-His scAb. B) Scheme of MeVac genomes encoding FmIL-12 or anti-PD-Li or IgG 1 -Fc retargeted to human CD20.
MeVac H gene was fully retargeted to human CD20 antigen by ablating attachment to the natural receptors, fusing the H protein to a single chain antibody (scAb) against the CD20 and including a six-histidine tag at the C terminus to allow specific transduction of murine melanoma B16-CD20 cells via human CD20 antigen and Vero-aHis cells via anti-His scAb.
The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.
Examples Example 1: Cell culture
- 40 -Vero African green monkey kidney cells were obtained from the American Type Culture Collection (Manassas, VA). Vero-aHis cell line stably expressing a single chain antibody (scAb) against His6 tag (Nakamura et al. 2005) was a kind gift of S.
J. Russel (Mayo Clinic, Rochester, MN). Murine colon adenocarcinoma cells MC38cea (transduced for stable expression of human CEA antigen) and the parental MC38 cell line were a gift of R. Cattaneo (Mayo Clinic, Rochester, MN). B16-CD20 have previously been generated by transducing the parental cell line with a lentiviral vector encoding human CD20 (Engeland et al. 2014). All cell lines were cultivated in either Dulbecco's modified Eagle's medium (DMEM;
Life Technologies, Darmstadt, Germany) or Roswell Park Memorial Institute 1640 medium (RPMI 1640; Life Technologies) supplemented with 10% Fetal Calf Serum (FCS) at 37 C in a humidified atmosphere with 5% CO2 and routinely tested for mycoplasma contamination.
Example 2: Cloning of recombinant MeVac genomes The cDNA plasmids encoding recombinant MeV genomes were constructed on the basis of the commercially used Schwarz/Moraten vaccine strain (MeVac) (Combredet et al.
2003). Transgenes were inserted in additional transcription units (ATUs) containing additional gene-end gene-start signals and a unique cloning site. Transgenes smaller than 1 kbp including murine GM-CSF (426 bp), murine IP-10 (312 bp) and eGFP (720 bp) were inserted into the leader position of pcMeVac as MluI-Ascl fragments via the unique AscI
restriction site. The mGM-CSF and eGFP fragments were amplified from the MeV
Edmonston B (NSe) vaccine strain genomes encoding the respective transgenes (Grossardt et al. 2013). The mIP-10 (mCxc//0) gene was amplified with primers flanking the novel construct and adding a M/u/ site and a Kozak sequence (GCCACC) in the 5'-end and a two nucleotide TA spacer and AscI site in the 3'-end using cDNA obtained from murine splenocytes.
Cassette encoding a murine IL-12 fusion protein (FmIL-12) consisting of murine IL-12 p40 and p35 subunits linked by a (Gly4Ser)3 for insertion into MeV genome had previously been constructed by C. Grossardt (Grossardt 2013) based on results of Lieschke and colleagues (Lieschke et al. 1997). FmIL-12 construct (1650 bp) was excised from pCG
expression vector (constructed by C. Grossardt) as Paul-MluI fragment and inserted into the MeVac genome downstream the P ORF via the unique MauBI cloning site.
J. Russel (Mayo Clinic, Rochester, MN). Murine colon adenocarcinoma cells MC38cea (transduced for stable expression of human CEA antigen) and the parental MC38 cell line were a gift of R. Cattaneo (Mayo Clinic, Rochester, MN). B16-CD20 have previously been generated by transducing the parental cell line with a lentiviral vector encoding human CD20 (Engeland et al. 2014). All cell lines were cultivated in either Dulbecco's modified Eagle's medium (DMEM;
Life Technologies, Darmstadt, Germany) or Roswell Park Memorial Institute 1640 medium (RPMI 1640; Life Technologies) supplemented with 10% Fetal Calf Serum (FCS) at 37 C in a humidified atmosphere with 5% CO2 and routinely tested for mycoplasma contamination.
Example 2: Cloning of recombinant MeVac genomes The cDNA plasmids encoding recombinant MeV genomes were constructed on the basis of the commercially used Schwarz/Moraten vaccine strain (MeVac) (Combredet et al.
2003). Transgenes were inserted in additional transcription units (ATUs) containing additional gene-end gene-start signals and a unique cloning site. Transgenes smaller than 1 kbp including murine GM-CSF (426 bp), murine IP-10 (312 bp) and eGFP (720 bp) were inserted into the leader position of pcMeVac as MluI-Ascl fragments via the unique AscI
restriction site. The mGM-CSF and eGFP fragments were amplified from the MeV
Edmonston B (NSe) vaccine strain genomes encoding the respective transgenes (Grossardt et al. 2013). The mIP-10 (mCxc//0) gene was amplified with primers flanking the novel construct and adding a M/u/ site and a Kozak sequence (GCCACC) in the 5'-end and a two nucleotide TA spacer and AscI site in the 3'-end using cDNA obtained from murine splenocytes.
Cassette encoding a murine IL-12 fusion protein (FmIL-12) consisting of murine IL-12 p40 and p35 subunits linked by a (Gly4Ser)3 for insertion into MeV genome had previously been constructed by C. Grossardt (Grossardt 2013) based on results of Lieschke and colleagues (Lieschke et al. 1997). FmIL-12 construct (1650 bp) was excised from pCG
expression vector (constructed by C. Grossardt) as Paul-MluI fragment and inserted into the MeVac genome downstream the P ORF via the unique MauBI cloning site.
-41 -Antibodies against negative murine T cell regulators CTLA-4 and PD-Li as well as soluble form of murine CD80 T cell costimulatory molecule and human IgG1 -Fc fragment for use as a control were inserted into the ATU downstream the H gene.
Cassettes encoding antibodies against murine CTLA-4 and PD-Li and human IgG1 -Fc fragment previously designed by C. E. Engeland (Engeland et al. 2014) were used as templates. The respective constructs were excised from pCG expression vectors as MluI-Paul fragments and inserted into the pcMeVac H-ATU via the unique MauBI cloning site.
Murine CD80 molecule was inserted for expression from MeVac in a soluble form.
CD80-Fc was constructed by fusing the extracellular part of the murine CD80 with the same human IgG1 -Fc region as used in both anti-CTLA-4 and anti-PD-Li constructs via fusion PCR. The first PCR fragment consisting of the MluI restriction site followed by Kozak sequence (GCCACC), murine CD80 signal peptide, extracellular part (up to the asparagine in position 246) of murine CD80 and first 26 nucleotides of the hinge of IgGl-Fc was synthesized using pCG vector encoding murine CD80 as a template. The second PCR
fragment consisting of the human IgG 1 -Fe region followed by myc tag, stop codon and AscI
restriction site was synthesized using pCG vector encoding human IgG 1-Pc as a template. The obtained PCR products were fused with flanking primers in an overlap PCR
obtaining the mCD8O-Fc construct of 1614 bp. The mCD8O-Fc was inserted into the pcMeVac H-ATU as a Mlul-AscI fragment via the unique MauBI cloning site.
MeVac genomes encoding the previously described transgenes with a fully retargeted MeV H attachment gene were constructed to allow targeted transduction of murine MC38cea and B16-CD20 cells. MeVac H gene was exchanged for H gene with mutated attachment sites to the natural MeV receptors CD46 and CD150, fused to a single chain antibody (scAb) against human CEA or CD20 and containing a C-terminal His6 tag. The retargeting system allows a flexible change of the targeted antigen by exchanging the specific scAb as a SfiI-Notl fragment.
Example 3: Virus propagation and titration Recombinant MeVac particles were obtained from cDNA constructs according to Radecke et al. (Radecke et al. 1995) and propagated on Vero-allis cells according to
Cassettes encoding antibodies against murine CTLA-4 and PD-Li and human IgG1 -Fc fragment previously designed by C. E. Engeland (Engeland et al. 2014) were used as templates. The respective constructs were excised from pCG expression vectors as MluI-Paul fragments and inserted into the pcMeVac H-ATU via the unique MauBI cloning site.
Murine CD80 molecule was inserted for expression from MeVac in a soluble form.
CD80-Fc was constructed by fusing the extracellular part of the murine CD80 with the same human IgG1 -Fc region as used in both anti-CTLA-4 and anti-PD-Li constructs via fusion PCR. The first PCR fragment consisting of the MluI restriction site followed by Kozak sequence (GCCACC), murine CD80 signal peptide, extracellular part (up to the asparagine in position 246) of murine CD80 and first 26 nucleotides of the hinge of IgGl-Fc was synthesized using pCG vector encoding murine CD80 as a template. The second PCR
fragment consisting of the human IgG 1 -Fe region followed by myc tag, stop codon and AscI
restriction site was synthesized using pCG vector encoding human IgG 1-Pc as a template. The obtained PCR products were fused with flanking primers in an overlap PCR
obtaining the mCD8O-Fc construct of 1614 bp. The mCD8O-Fc was inserted into the pcMeVac H-ATU as a Mlul-AscI fragment via the unique MauBI cloning site.
MeVac genomes encoding the previously described transgenes with a fully retargeted MeV H attachment gene were constructed to allow targeted transduction of murine MC38cea and B16-CD20 cells. MeVac H gene was exchanged for H gene with mutated attachment sites to the natural MeV receptors CD46 and CD150, fused to a single chain antibody (scAb) against human CEA or CD20 and containing a C-terminal His6 tag. The retargeting system allows a flexible change of the targeted antigen by exchanging the specific scAb as a SfiI-Notl fragment.
Example 3: Virus propagation and titration Recombinant MeVac particles were obtained from cDNA constructs according to Radecke et al. (Radecke et al. 1995) and propagated on Vero-allis cells according to
- 42 -Nakamura et al. (Nakamura et al. 2005). For propagation Vero-aHis cells were infected at a multiplicity of infection (MOI) of 0.03 and cultivated at 37 C 5% CO2 until syncytia had spread across the whole cell layer (36 - 48 h post infection). Subsequently culture medium was completely removed, cells were scraped and collected and viral particles released by one freeze-thaw cycle. Cellular debris was removed by centrifugation at 6000x g for 5min. The amount of viral particles was determined by 1:10 serial dilution titrations in octuplicates on 1.5x104 Vero-aHis cells per well in 96-well cell culture plates. Individual syncytia were counted 72h post infection and titers calculated as cell infectious units per ml (ciu/ml).
Example 4: Statistical analyses Statistical analyses were performed using GraphPad Prism software (version 5.04; GraphPad Software, La Jolla, CA). Tumor volumes and ELISA results in restimulation experiments were analysed by one-way ANOVA with Tukey's multiple comparison test. Survival curves were analyzed by log-rank (Mantel-Cox) test with Bonferroni-Holm correction for multiple comparisons. Result was considered statistically significant if p value was lower than 0.05 after correcting for multiple comparisons.
Example 5: Characterization of virus replication Vero-aHis and MC38cea cells were seeded in 12-well plates (1x105 cells per well). After 12h the cell culture medium was removed and cells were infected with the respective viruses at MOI=3 in 300 I OptiMEM in triplicates for each time point and cultivated at 37 C 5% CO2.
After adsorption for ca. 2h the inoculum was removed and substituted with 1 ml DMEM+10% FCS per well. Cells were scraped in the culture medium at the designated time points, collected and snap frozen in liquid nitrogen. The amount of viral particles was determined by 1:10 serial dilution titrations in quadruplicates on 1.5 x104 Vero-aHis cells per well in 96-well cell culture plates. Individual syncytia were counted 72h post infection and titers calculated as ciu/ml.
Example 6: Assessment of virus cytotoxic potential in vitro MC38cea cells were seeded in 6-well plates (2x105 cells per well). After 12h the cell culture medium was removed and cells were infected with the respective viruses at M01=5 in 800 I
Example 4: Statistical analyses Statistical analyses were performed using GraphPad Prism software (version 5.04; GraphPad Software, La Jolla, CA). Tumor volumes and ELISA results in restimulation experiments were analysed by one-way ANOVA with Tukey's multiple comparison test. Survival curves were analyzed by log-rank (Mantel-Cox) test with Bonferroni-Holm correction for multiple comparisons. Result was considered statistically significant if p value was lower than 0.05 after correcting for multiple comparisons.
Example 5: Characterization of virus replication Vero-aHis and MC38cea cells were seeded in 12-well plates (1x105 cells per well). After 12h the cell culture medium was removed and cells were infected with the respective viruses at MOI=3 in 300 I OptiMEM in triplicates for each time point and cultivated at 37 C 5% CO2.
After adsorption for ca. 2h the inoculum was removed and substituted with 1 ml DMEM+10% FCS per well. Cells were scraped in the culture medium at the designated time points, collected and snap frozen in liquid nitrogen. The amount of viral particles was determined by 1:10 serial dilution titrations in quadruplicates on 1.5 x104 Vero-aHis cells per well in 96-well cell culture plates. Individual syncytia were counted 72h post infection and titers calculated as ciu/ml.
Example 6: Assessment of virus cytotoxic potential in vitro MC38cea cells were seeded in 6-well plates (2x105 cells per well). After 12h the cell culture medium was removed and cells were infected with the respective viruses at M01=5 in 800 I
- 43 -OptiMEM in triplicates for each time point and cultivated at 37 C 5% CO2.
After adsorption for ca. 2h the inoculum was removed and substituted with 2 ml DMEM+10% FCS per well.
At the designated time points cell viability was determined using Colorimetric Cell Viability Kit III (XTT) (PromoKine, Heidelberg, Germany) according to instructions of the manufacturer.
Example 7: Characterization of transgene expression MC38cea cells were seeded in 12-well plates (1x105 cells per well). After 12h the cell culture medium was removed and cells were infected with the respective viruses at M0I=3 in 300 ill OptiMEM in triplicates for each time point and cultivated at 37 C 5% CO2.
After adsorption for ca. 2h 700 al DMEM+10% FCS per well was added. Supernatants were collected at the designated time points. Time point Oh was represented by inoculum in OptiMEM
used for infection. Expression of the respective immunomodulators was detected by ELISA.
Commercially available ELISA kits were used for detection of mGM-CSF, FmIL-12, mIP-10 (R&D Systems, Wiesbaden, Germany) and CD8O-Fc (Boster Biological Technology, Offenbach, Germany) according to instructions of the manufacturer. Anti-CTLA-4 and anti-PD-Li were detected by binding to their respective murine proteins. Ninety-six well plates (Nunc Maxisorp, Thermo Fisher Scientific, Schwerte, Germany) were coated with 100 ng recombinant His-tagged murine CTLA-4 or PD-Li (Life Technologies). Wells were blocked and 100 al of the respective samples were added and incubated for 2h. After washing the antibodies were detected with anti-human IgG-Fc Biotin (clone HP-6071; Sigma-Aldrich, Taufkirchen, Germany), Peroxidase conjugated Streptavidin (Dianova, Hamburg, Germany) and 1-Step Ultra-TMB ELISA Substrate Solution (Thermo Scientific, Karlsruhe, Germany).
Absorbance was measured using Infinite M200 Pro microplate reader and i-control software (Tecan, Mannedorf, Switzerland).
Example 8: Flow cytometry for detection of anti-PD-Li binding to MC38cea cells Vero-aHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding anti-PD-Li or IgGl-Fc with MOI=0.03. Supernatants were collected (15m1 per plate) when syncytia had spread over the whole cell layer (ca. 36h post infection). lx106 MC38cea cells were incubated with anti-PD-L1 or IgG 1-Fe containing supernatant previously collected from
After adsorption for ca. 2h the inoculum was removed and substituted with 2 ml DMEM+10% FCS per well.
At the designated time points cell viability was determined using Colorimetric Cell Viability Kit III (XTT) (PromoKine, Heidelberg, Germany) according to instructions of the manufacturer.
Example 7: Characterization of transgene expression MC38cea cells were seeded in 12-well plates (1x105 cells per well). After 12h the cell culture medium was removed and cells were infected with the respective viruses at M0I=3 in 300 ill OptiMEM in triplicates for each time point and cultivated at 37 C 5% CO2.
After adsorption for ca. 2h 700 al DMEM+10% FCS per well was added. Supernatants were collected at the designated time points. Time point Oh was represented by inoculum in OptiMEM
used for infection. Expression of the respective immunomodulators was detected by ELISA.
Commercially available ELISA kits were used for detection of mGM-CSF, FmIL-12, mIP-10 (R&D Systems, Wiesbaden, Germany) and CD8O-Fc (Boster Biological Technology, Offenbach, Germany) according to instructions of the manufacturer. Anti-CTLA-4 and anti-PD-Li were detected by binding to their respective murine proteins. Ninety-six well plates (Nunc Maxisorp, Thermo Fisher Scientific, Schwerte, Germany) were coated with 100 ng recombinant His-tagged murine CTLA-4 or PD-Li (Life Technologies). Wells were blocked and 100 al of the respective samples were added and incubated for 2h. After washing the antibodies were detected with anti-human IgG-Fc Biotin (clone HP-6071; Sigma-Aldrich, Taufkirchen, Germany), Peroxidase conjugated Streptavidin (Dianova, Hamburg, Germany) and 1-Step Ultra-TMB ELISA Substrate Solution (Thermo Scientific, Karlsruhe, Germany).
Absorbance was measured using Infinite M200 Pro microplate reader and i-control software (Tecan, Mannedorf, Switzerland).
Example 8: Flow cytometry for detection of anti-PD-Li binding to MC38cea cells Vero-aHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding anti-PD-Li or IgGl-Fc with MOI=0.03. Supernatants were collected (15m1 per plate) when syncytia had spread over the whole cell layer (ca. 36h post infection). lx106 MC38cea cells were incubated with anti-PD-L1 or IgG 1-Fe containing supernatant previously collected from
- 44 -one fully infected 15 cm dish for 1 h with rotation at room to. After washing the bound anti-PD-Li was detected by staining with anti-HA (clone HA-7; Sigma-Aldrich) and goat anti-mouse IgG PE (polyclonal; BD Biosciences, Heidelberg, Germany). The stained cells were resuspended in DPBS with 0.2 g/m1 DAPI (Sigma-Aldrich) and directly acquired on LSRII
flow cytometer (BD Biosciences) collecting at least 10000 events per sample.
Example 9: Isolation of murine splenocytes Spleens were aseptically isolated and maintained in RPMI 1640 (Life Technologies, Darmstadt, Germany) at 4 C until further processing. Spleen was passed through a 100 im nylon cell strainer (BD Biosciences, Heidelberg, Germany) into 10 ml RPMI 1640 and cells were pelleted at 300xg for 5min. For red blood cell lysis pellet was resuspended in 1 ml ACK
Lysing solution (Life Technologies), incubated 10min at room t and centrifuged at 300xg for 5min. Cells were resuspended in DPBS (Life Technologies) and cell concentration determined using Neubauer hemocytometer and Trypan blue (Sigma-Aldrich) staining for dead cell exclusion.
Example 10: Functional assay for MeVac encoded anti-PD-L1, CD8O-Fc and anti-Vero-aHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding anti-PD-L1, anti-CTLA-4, CD8O-Fc or IgG 1 -Fc with MOI=0.03.
Supernatants were collected (15ml per plate) when syncytia had spread over the whole cell layer (ca. 36h post infection). 2x105 MC38cea cells were incubated with 2m1 medium collected from the Vero-aHis infected with the respective viruses for 5min with rotation at room t and pelleted by centrifugation 5min at 300xg. The procedure was repeated six times. The treated cells were resuspended in 100 .1 activation medium ¨ RPMI 1640 supplemented with 5% FCS, 1%
Penicillin-Streptomycin (Life Technologies), 500 l_t1\4 ionomycin (Cayman Chemical Company, Hamburg, Germany) and 5 iM PMA (Cayman Chemical Company) and seeded in 96-well plate. 2x105 freshly isolated splenocytes from C57BL/6J mouse in 100 Ill activation medium were added per each well with the treated MC38cea cells. Cells were cocultivated 24h at 37 C 5% CO2 and supernatants collected subsequently. IFN-y concentration was determined using mouse IFN gamma ELISA Ready-SET-Go! (eBioscience, Frankfurt am Main, Germany) according to the instructions of the manufacturer.
flow cytometer (BD Biosciences) collecting at least 10000 events per sample.
Example 9: Isolation of murine splenocytes Spleens were aseptically isolated and maintained in RPMI 1640 (Life Technologies, Darmstadt, Germany) at 4 C until further processing. Spleen was passed through a 100 im nylon cell strainer (BD Biosciences, Heidelberg, Germany) into 10 ml RPMI 1640 and cells were pelleted at 300xg for 5min. For red blood cell lysis pellet was resuspended in 1 ml ACK
Lysing solution (Life Technologies), incubated 10min at room t and centrifuged at 300xg for 5min. Cells were resuspended in DPBS (Life Technologies) and cell concentration determined using Neubauer hemocytometer and Trypan blue (Sigma-Aldrich) staining for dead cell exclusion.
Example 10: Functional assay for MeVac encoded anti-PD-L1, CD8O-Fc and anti-Vero-aHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding anti-PD-L1, anti-CTLA-4, CD8O-Fc or IgG 1 -Fc with MOI=0.03.
Supernatants were collected (15ml per plate) when syncytia had spread over the whole cell layer (ca. 36h post infection). 2x105 MC38cea cells were incubated with 2m1 medium collected from the Vero-aHis infected with the respective viruses for 5min with rotation at room t and pelleted by centrifugation 5min at 300xg. The procedure was repeated six times. The treated cells were resuspended in 100 .1 activation medium ¨ RPMI 1640 supplemented with 5% FCS, 1%
Penicillin-Streptomycin (Life Technologies), 500 l_t1\4 ionomycin (Cayman Chemical Company, Hamburg, Germany) and 5 iM PMA (Cayman Chemical Company) and seeded in 96-well plate. 2x105 freshly isolated splenocytes from C57BL/6J mouse in 100 Ill activation medium were added per each well with the treated MC38cea cells. Cells were cocultivated 24h at 37 C 5% CO2 and supernatants collected subsequently. IFN-y concentration was determined using mouse IFN gamma ELISA Ready-SET-Go! (eBioscience, Frankfurt am Main, Germany) according to the instructions of the manufacturer.
- 45 -Example 11: Functional assay for MeVac encoded FmIL-12 Vero-aHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding FmIL-12 or eGFP. Supernatants were collected (15m1 per plate) when syncytia had spread over the whole cell layer (ca. 36h post infection). FmIL-12 concentration was assessed using Mouse IL-12 p70 Quantikine ELISA Kit (R&D Systems). 2x106 freshly isolated splenocytes from a C57BL/6J mouse were resuspended in RPMI 1640 supplemented with 10% FCS, 1% Penicillin-Streptomycin solution and 50 U/ml recombinant murine IL-(Miltenyi, Bergisch Gladbach, Germany) with varying concentrations of MeVac encoded FmIL-12 or respective parts of supernatant from cells infected with eGFP
encoding MeVac.
Splenocytes were seeded in 12-well plates and incubated 48h at 37 C 5% CO2.
Supernatants were collected and IFN-y concentration assessed using mouse IFN gamma ELISA
Ready-SET-Go!O (eBioscience) according to the instructions of the manufacturer.
Example 12: Assessment of therapeutic efficacy in vivo MC38cea cells were subcutaneously (s.c.) implanted into six to eight weeks old mice (Harlan Laboratories, Rossdorf Germany or DKFZ, Heidelberg, Germany).
When average tumor volume reached 50 ¨ 100 mm3 (depending on experiment) treatment was initiated. Mice received intratumoral (i.t.) injections with the respective viruses on four or five consecutive days with 5x105 or 1x106 ciu in 100 al. Mice in the mock group received treatment with 100 1 OptiMEM. Tumor volume was determined every third day measuring largest and smallest diameter with a caliper and calculating the volume using a formula:
largest diameterx(smallest diameter)2x0.5. Mice were sacrificed when tumor volume exceeded 1500 mm3, ulceration occurred or signs of severe illness were observed.
Example 13: Antigen specific IFN-y memory recall with murine splenocytes MC38cea, MC38 and B16 cells were treated with 20 ag/ml mitomycin-C (Sigma-Aldrich) for 2h with shaking at 37 C. After subsequent washing three times with DPBS cells were resuspended in activation medium containing RPMI 1640 supplemented with 10%
FCS, 1%
Penicillin-Streptomycin and 50 U/ml recombinant murine IL-2. Freshly isolated murine splenocytes were resuspended in the same activation medium. Cocultures were prepared in
encoding MeVac.
Splenocytes were seeded in 12-well plates and incubated 48h at 37 C 5% CO2.
Supernatants were collected and IFN-y concentration assessed using mouse IFN gamma ELISA
Ready-SET-Go!O (eBioscience) according to the instructions of the manufacturer.
Example 12: Assessment of therapeutic efficacy in vivo MC38cea cells were subcutaneously (s.c.) implanted into six to eight weeks old mice (Harlan Laboratories, Rossdorf Germany or DKFZ, Heidelberg, Germany).
When average tumor volume reached 50 ¨ 100 mm3 (depending on experiment) treatment was initiated. Mice received intratumoral (i.t.) injections with the respective viruses on four or five consecutive days with 5x105 or 1x106 ciu in 100 al. Mice in the mock group received treatment with 100 1 OptiMEM. Tumor volume was determined every third day measuring largest and smallest diameter with a caliper and calculating the volume using a formula:
largest diameterx(smallest diameter)2x0.5. Mice were sacrificed when tumor volume exceeded 1500 mm3, ulceration occurred or signs of severe illness were observed.
Example 13: Antigen specific IFN-y memory recall with murine splenocytes MC38cea, MC38 and B16 cells were treated with 20 ag/ml mitomycin-C (Sigma-Aldrich) for 2h with shaking at 37 C. After subsequent washing three times with DPBS cells were resuspended in activation medium containing RPMI 1640 supplemented with 10%
FCS, 1%
Penicillin-Streptomycin and 50 U/ml recombinant murine IL-2. Freshly isolated murine splenocytes were resuspended in the same activation medium. Cocultures were prepared in
- 46 -24-well plates seeding 1 x105 mitomycin-c treated tumor cells or 1 x106 ciu MeVac with 1 x106 splenocytes per well in 0.5 ml total volume of activation medium. As controls 1 x106 splenocytes were cocultivated also with Vero-anis or DLD-1 cell lysates prepared by lysis of 1 x106 cells per ml with one freeze-thaw cycle. Cells were cocultivated for 48h, supernatants collected and IFN-y concentration assessed using mouse IFN gamma ELISA Ready-SET-Go! (eBioscience) according to the instructions of the manufacturer.
References (Examples) Combredet, C. et al., 2003. A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice.
Engeland, C.E. et al., 2014. CTLA-4 and PD-Li Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. Molecular Therapy, 22(11), pp.1949-1959.
Grossardt, C., 2013. Engineering Targeted and Cytokine-armed Oncolytic Measles Viruses.
Ruperto-Carola University of Heidelberg.
Grossardt, C. et al., 2013. Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine. Human Gene Therapy, 24(7), pp.644-654.
Lieschke, G.J. et al., 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nature biotechnology, 15(1), pp.35-40.
Nakamura, T. et al., 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nature biotechnology, 23(2), pp.209-14.
Radecke, F. et al., 1995. Rescue of measles viruses from cloned DNA. The EMBO
journal, 14(23), pp.5773-84. Available at:
References (Examples) Combredet, C. et al., 2003. A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice.
Engeland, C.E. et al., 2014. CTLA-4 and PD-Li Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. Molecular Therapy, 22(11), pp.1949-1959.
Grossardt, C., 2013. Engineering Targeted and Cytokine-armed Oncolytic Measles Viruses.
Ruperto-Carola University of Heidelberg.
Grossardt, C. et al., 2013. Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine. Human Gene Therapy, 24(7), pp.644-654.
Lieschke, G.J. et al., 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nature biotechnology, 15(1), pp.35-40.
Nakamura, T. et al., 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nature biotechnology, 23(2), pp.209-14.
Radecke, F. et al., 1995. Rescue of measles viruses from cloned DNA. The EMBO
journal, 14(23), pp.5773-84. Available at:
Claims (20)
1. A recombinant virus of the family Paramyxoviridae, comprising an expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12.
2. The recombinant virus of the family Paramyxoviridae of claim 1, wherein said p35 subunit and said p40 subunit of said IL-12 fusion polypeptide are a mouse p35 subunit and a mouse p40 subunit or a variant thereof, preferably are a human p35 subunit and a human p40 subunit or a variant thereof.
3. The recombinant virus of the family Paramyxoviridae of claim 1, wherein said IL-12 fusion polypeptide comprises the structure p35-linker-p40.
4. The recombinant virus of the family Paramyxoviridae of claim 1, wherein said linker is -(glycine4-serine)n-, with n=1 to 10, preferably n=2 to 5, more preferably n=3.
5. The recombinant virus of the family Paramyxoviridae of claim 1, further comprising at least one expressible polynucleotide encoding a further activator of the immune response.
6. The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is a secreted immunoglobulin.
7. The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is an Fc domain of an antibody.
8. The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is a secreted soluble activator of the immune response.
9. The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is a secreted soluble anti-PD-L1 antibody.
10. The recombinant virus of the family Paramyxoviridae of claim 1, wherein said recombinant virus is a recombinant Morbillivirus, preferably, a recombinant measles virus (MV).
11. The recombinant virus of the family Paramyxoviridae of claim 1, wherein said recombinant MV is derived from MV strain Edmonston A or B, preferably B, or, more preferably, from vaccine strain Schwarz/Moraten..
12. The recombinant virus of the family Paramyxoviridae of claim 1, wherein the at least one expressible polynucleotide encoding an IL-12 polypeptide is comprised in a polynucleotide encoding the recombinant virus of the family Paramyxoviridae.
13. The recombinant virus of the family Paramyxoviridae of claim 1, wherein said polynucleotide encoding the recombinant virus of the family Paramyxoviridae comprises the nucleic acid sequence of any one of SEQ ID NOs:4 to 7, 14, and 15.
14. A medicament comprising (a) (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according to claim 1, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and (b) at least one pharmacologically acceptable excipient.
(ii) a recombinant virus of the family Paramyxoviridae according to claim 1, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or (v) any combination of (i) to (iv); and (b) at least one pharmacologically acceptable excipient.
15. A method for treating cancer in a subject afflicted with cancer, comprising a) contacting said subject with (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of claim 1, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii);
or (v) any combination of (i) to (iv); and, thereby, b) treating cancer in a subject afflicted with cancer.
(ii) a recombinant virus of the family Paramyxoviridae according of claim 1, (iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii);
or (v) any combination of (i) to (iv); and, thereby, b) treating cancer in a subject afflicted with cancer.
16. The method of claim 15, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide and not comprising an expressible polynucleotide encoding a ligand for an immune checkpoint blockade protein.
17. The method of claim 15, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide as the only expressible polynucleotide encoding an activator of the immune response.
18. The method of claim 15, wherein said cancer is a solid cancer, a metastasis, or a relapse thereof.
19. The method of claim 15, wherein treating cancer is reducing tumor burden.
20. The method of claim 15, wherein said cancer is malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2921864A CA2921864C (en) | 2016-02-25 | 2016-02-25 | Rna viruses expressing il-12 for immunovirotherapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2921864A CA2921864C (en) | 2016-02-25 | 2016-02-25 | Rna viruses expressing il-12 for immunovirotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2921864A1 true CA2921864A1 (en) | 2017-08-25 |
CA2921864C CA2921864C (en) | 2021-08-31 |
Family
ID=59678007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2921864A Active CA2921864C (en) | 2016-02-25 | 2016-02-25 | Rna viruses expressing il-12 for immunovirotherapy |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2921864C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112442504A (en) * | 2020-12-10 | 2021-03-05 | 电子科技大学 | Preparation method of recombinant grass carp interleukin-12 active protein |
-
2016
- 2016-02-25 CA CA2921864A patent/CA2921864C/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112442504A (en) * | 2020-12-10 | 2021-03-05 | 电子科技大学 | Preparation method of recombinant grass carp interleukin-12 active protein |
CN112442504B (en) * | 2020-12-10 | 2023-01-24 | 电子科技大学 | Preparation method of recombinant grass carp interleukin-12 active protein |
Also Published As
Publication number | Publication date |
---|---|
CA2921864C (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190315825A1 (en) | Rna viruses expressing il-12 for immunovirotherapy | |
Winkler et al. | Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection | |
JP7077377B2 (en) | Oncolytic virus for expression of immune checkpoint modulator | |
US20210252085A1 (en) | Rna viruses for immunovirotherapy | |
ES2808153T3 (en) | Combination therapy for disease treatment | |
RU2698975C2 (en) | Fused immunomodulatory proteins and methods for production thereof | |
JP6359492B2 (en) | Method for treating cancer with anti-IL-1α antibody | |
CN102702358A (en) | Antibody against the CSF-1 R | |
KR20070085314A (en) | Recombinant newcastle disease virus | |
RU2678810C2 (en) | CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | |
US20190099461A1 (en) | Rna viruses for immunovirotherapy | |
KR20100113096A (en) | Attenuated oncolytic paramyxoviruses encoding avian cytokines | |
CA3024653A1 (en) | Pseudotyped oncolytic rhabdoviruses and their use in combination therapy | |
AU2023282166A1 (en) | Measles Virus Encoding a Tumor Antigen | |
US20230101046A1 (en) | Anaplastic lymphoma kinase chimeric antigen receptors and methods of use | |
CA2921864C (en) | Rna viruses expressing il-12 for immunovirotherapy | |
CN112912398A (en) | Novel antibodies and nucleotide sequences and uses thereof | |
KR20230107666A (en) | Oncolytic herpes simplex virus type 1 for the treatment of brain tumors | |
TW202309072A (en) | Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof | |
TW202206449A (en) | Recombinant vaccinia virus | |
KR102550094B1 (en) | Tumor targeting protein or fragment thereof, antibody against it and use thereof | |
US20220305082A1 (en) | Chimeric antigen receptor specifically binding to cd 300c antigen or receptor thereof | |
CA3197371A1 (en) | Oncolytic immunotherapy by tumor micro-environment remodeling | |
AU2022280586A1 (en) | Chimeric antigen receptor specifically binding to cd300c antigen or receptor thereof | |
CA3172530A1 (en) | Ror1 targeting chimeric antigen receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20201216 |